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ABSTRACT
THE ROLE OF YKL-40 IN THE PROGRESSION OF GLIOBLASTOMA
September 2013
RALPH A. FRANCESCONE, B.S., MERRIMACK COLLEGE
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Rong Shao
Glioblastoma Multiforme (GBM) is the most common brain cancer and one of the most fatal
forms of cancer overall. The average survival time is 10-14 months, and less than 10% of patients
survive more than 5 years after diagnosis. It is characterized by extreme vasculature,
chemo/radioresistance, and invasiveness into the normal brain. The current standard of care, which
includes surgical removal of tumor, radiation, and the chemotherapeutic agent temozolomide,
initially stunt tumor growth. Nevertheless, the tumor invariably rebounds and the patient succumbs
to the disease. Therefore, there is an urgent need to develop new therapies for this devastating
disease.
YKL-40 is one of the most over-expressed proteins by GBM cells, and is elevated in the
serum of patients with GBM. YKL-40 is implicated in a host of inflammatory diseases and has been
shown to play a major role in the maturation of some cells of the immune system, especially
macrophages. Thus, it has been suggested that YKL-40 may act as a prognostic biomarker for cancer
and inflammatory disease. However, little is known about the role of YKL-40 in relation to cancer
development and progression, and more work needs to be done to validate it as a biomarker or as a
therapeutic target.
It was the goal of the work described herein to uncover some of the key molecular
mechanisms of GBM development and progression in the hopes of offering new therapeutic targets.
Using a wide variety of in vitro and in vivo techniques, the role of a secreted glycoprotein YKL-40 in
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GBM was probed. It was demonstrated that YKL-40 enhanced angiogenesis, radioresistance, and
progression of GBM cells. Moreover, inhibition of YKL-40 in mouse models markedly arrested tumor
growth and vascularization, lending support to the idea of YKL-40 as a therapeutic target. Finally,
YKL-40 drove GBM cells into a mesenchymal phenotype, where the tumor cells act as mural-like cells,
supporting tumor vasculature networks. Hopefully, the results from these studies will offer the
rationale to develop drugs against YKL-40 and potentially extend the lives of patients with this
terrible disease.
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CHAPTER 1
INTRODUCTION: GLIOBLASTOMA AND YKL-40

1.1 YKL-40
YKL-40 is a secreted glycoprotein that was first discovered in the medium of a human
osteosarcoma cell line, MG-63 (Johansen, Williamson, et al. 1992). It is a 40 kDa protein named
after its first three amino acids; tyrosine, lysine, and leucine. YKL-40 has a 53% sequence
homology to a member of the family 18 chitinases, which bind to and catabolize chitin (Fusetti,
et al. 2003). While YKL-40 can directly bind to chitin, it lacks the glycosyl hydrolase activity to
break down chitin (Fusetti, et al. 2003, Renkema, et al. 1998). Therefore, YKL-40 is deemed a
“chitinase-like protein” and its gene product is known as chitinase 3 like 1 protein (CHI3L1).
With respect to normal physiology, YKL-40 is expressed by activated neutrophils,
macrophages, vascular smooth muscle cells, and chondrocytes (Junker, Johansen and
Andersen, et al. 2005, Johansen, Baslund, et al. 1999, Volck, Ostergaard, et al. 1999, Volck,
Price, et al. 1998, Recklies, White and Ling 2002, Shackelton, Mann and Millis 1995). Moreover,
it is expressed at all stages of early human muscle and skeletal development (Johansen, Høyer,
et al. 2007). YKL-40 has been shown to play a role in extracellular matrix remodeling,
macrophage induced inflammation, and T-cell function (Junker, Johansen and Andersen, et al.
2005, Johansen, Baslund, et al. 1999, Shackelton, Mann and Millis 1995, Lee, Hartl, et al. 2009,
Rathcke, Johansen and Vestergaard 2006). It has been demonstrated that YKL-40 is more highly
expressed in cells that are more metabolically active, and at sites of high cell turnover
(mammary involution, for example) (Ringsholt, et al. 2007). Therefore, YKL-40 is considered a
growth factor and this has been shown for fibroblasts, bone cells, and vascular smooth muscle

1

cells (Schultz and Johansen 2010, Recklies, White and Ling 2002, Shackelton, Mann and Millis
1995, Ringsholt, et al. 2007).
It has been demonstrated that YKL-40 is over-expressed in the serum of patients with a wide
variety of inflammatory diseases, diabetes, and cardiovascular diseases (Matsuura, et al. 2011,
Lee and Elias, Role of breast regression protein-39/YKL-40 in asthma and allergic responses
2010, Rathcke, Raymond, et al. 2010). Additionally, YKL-40 serum levels have been positively
correlated with shorter survival and tumor aggressiveness in many types of cancer, including
glioblastoma (Pelloski, Mahajan, et al. 2005, Cintin, Johansen, et al. 2002, Hogdall, et al. 2003,
Johansen, Christensen, et al. 2003, Jensen, Johansen and Price 2003, Bergmann, et al. 2005).
The actual function of YKL-40 in the progression of cancer is unknown. It is suggested that it
can act as a survival factor/growth factor for the cancer cells. Also, due to the link between
YKL-40 and inflammation, tumor associated macrophages that express high levels of YKL-40
have been implicated in the development of cancer. No known mechanisms have been
elucidated to confirm these suggestions.

1.2 Glioblastoma Multiforme
Glioblastoma Multiforme (GBM), commonly referred to as glioblastoma, is the most
lethal cancer, and the most common malignancy of the brain and central nervous system. It is
classified as a World Health Organization (WHO) grade IV tumor that carries an average survival
time of approximately 10-14 months (Van Meir, et al. 2010).
These tumors are extremely difficult to treat due to a wide variety of factors. First, they
are often heterogeneous in nature, made up of neurons, oligodendrocytes (insulates neurons),
and astrocytes (supporting glial cells). Thus, it is a complicated process to pinpoint one
particular mechanism for tumorigenesis or therapy. Second, these tumors are characterized by
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extreme vascularization, proliferation, radioresistance, and DNA repair (Van Meir, et al. 2010,
Wen and Kesari 2008).
Because of the complex nature of these tumors, GBM is often classified into distinct
subtypes in an attempt to guide research to develop targeted therapies. In general, there are
four subtypes that have been determined through extensive genomic analysis (Verhaak, et al.
2010, Sottoriva, et al. 2013, Phillips, et al. 2006). They are listed in order of best prognosis;
Neural, Pro-neural, Classical, and Mesenchymal. The neural and pro-neural subgroups most
closely mirror normal brain cells. These cases of GBM often contain the differentiation markers
of all three major brain cell types, which are neurons, oligodendrocytes, and astrocytes. They
also often have the best response to therapy (Verhaak, et al. 2010, Sottoriva, et al. 2013,
Phillips, et al. 2006). In contrast to the neural and pro-neural groups, classical and
mesenchymal tumors have a much worse prognosis and are much less differentiated (Carro, et
al. 2010, Verhaak, et al. 2010). Classical GBM tumors contain the most common mutations,
such as overamplification of EGFR, and deregulation of the cell cycle through the Ink4a/ARF
gene locus. The Mesenchymal subtype is the most aggressive and invasive form of GBM, and
also carries a considerable inflammatory component. YKL-40 has emerged as a key marker for
the mesenchymal phenotype, and is also correlated with the worst overall survival of GBM
patients (Pelloski, Mahajan, et al. 2005, Nigro, et al. 2005, Verhaak, et al. 2010).
In the past, the standard of care for glioblastoma has been surgical resection, radiation
therapy, and a frontline chemotherapeutic, such as a temozolomide (Van Meir, et al. 2010,
Wen and Kesari 2008). Recent discoveries have demonstrated the heterogeneity of GBM
tumors and the need for targeted therapies, such as anti-angiogenic agents. Additionally, a
mono-therapeutic approach will not succeed because these tumors will overcome the
treatment by overcompensating through another molecular mechanism. For example, there
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have been multiple studies showing the tumors treated with a humanized monoclonal antibody
against VEGF (bevacizumab or avastin) or small molecules against its receptor will initially
inhibit angiogenesis and tumor volume (Keunen, et al. 2011, de Groot, et al. 2010, Pàez-Ribes,
et al. 2009, di Tomaso, Snuderl, et al. 2011). Nevertheless, the tumor becomes more invasive
and spreads further into the normal brain tissue. GBM cells seem to maintain this phenotype
even after treatment ceases and continue to invade into the normal brain, detrimental to
overall patient survival (Pàez-Ribes, et al. 2009, di Tomaso, Snuderl, et al. 2011). Therefore,
new molecular targets specific to GBM need to be identified, as well as a multipronged
treatment regimen that will not allow the tumors to overcome a single targeted therapy.

1.3 GBM and YKL-40: A potential therapeutic target
YKL-40 is one of the most over-expressed proteins in the serum of glioblastoma patients
and in genome wide microarray data of GBM tumor tissue (Hormigo, et al. 2006, Nigro, et al.
2005). It has been associated with GBM tumor radioresistance and overall poor patient
prognosis (Pelloski, Mahajan, et al. 2005). Additionally, a siRNA knockdown of the VEGF gene in
the U87 GBM cell line up-regulated YKL-40 protein levels (Saidi, et al. 2008). Consequently, YKL40 is under heavy consideration as a tumor biomarker for all cancers, especially for
glioblastoma (Schultz and Johansen 2010). Despite these facts, almost nothing is known about
the mechanisms associated with YKL-40 and glioblastoma tumor progression. For that reason,
further study of YKL-40 at the molecular level is highly warranted.

1.4 Blood Vessel Architecture
Vasculature of the human body provides tissues with oxygen, nutrients and secreted
protein messages, while also moving toxic waste products away from those cells (Hofman and
Chen 2010 ). Vasculature contains three major entities: endothelial cells, basement membrane
4

glycoproteins, and pericytes (Kalluri 2003, Bergers and Benjamin 2003). First, vasculature
consists of an inner sheet of endothelial cells that is folded upon itself to create a long tube like
structure known as the vessel. Lining the outside of this vessel is a complex mixture of
extracellular matrix components, such as laminin, heparan sulfate proteoglycans, and collagen
(Kalluri 2003). This is known as the basement membrane of a blood vessel, and differs slightly
depending on the function of the tissue. The last major component of vasculature is the
pericyte, which is a type of cell that supports blood vessel stability and growth. These cells line
the outside of the vessel, making contact with the endothelial cells and the basement
membrane. The basic cellular organization of a vessel is illustrated in Figure 1.1.
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Figure 1.1. Basic Structure of a Vessel.
Vasculature comprises three major components: endothelial
cells, basement membrane, and pericytes. [Reproduced with
permission from (Kalluri 2003)]
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1.5 The Vasculature of Glioblastoma
GBM is one of the most vascularized tumors and, as a result, there are many different
types of vasculature that exist within brain tumors (Furnari, et al. 2007, Wen and Kesari 2008,
Hardee and Zagzag 2012, Brem, Cotran and Folkman 1972). The five distinct types of vasculature
that are present in GBM are as follows:
1.) Vascular co-option; 2.) Angiogenesis; 3.) Vasculogenesis; 4.) Vasculogenic Mimicry 5.) Tumor
Derived Endothelial Vessels
Vascular co-option is the process where tumor cells migrate toward pre-existing vessels
in the normal brain and grow around them to gain an initial blood supply (Holash, et al. 1999,
Hardee and Zagzag 2012). Chronologically, this is the first step for GBM tumors to become
vascularized. Next, once the tumor cells begin to proliferate, hypoxic and necrotic areas
develop in the expanding tumor. GBM cells respond by stimulating angiogenesis, the manner by
which cancerous cells recruit blood vessels to the tumor, and this becomes the predominant
form of vasculature in the growing GBM tumor (Bergers and Benjamin 2003, Carmeliet and Jain
2011, Hardee and Zagzag 2012). At this stage, it is unclear if the other three forms of vasculature
contribute significantly to the evolving GBM tumor. Nevertheless, new blood vessels can be
created by bone marrow stem cells, the process termed vasculogenesis, or from the tumor cells
themselves independent of endothelial cells, which is known as vasculogenic mimicry (Hardee
and Zagzag 2012, El Hallani, et al. 2010, Hendrix, et al. 2003). Lastly, glioblastoma stem cells can
differentiate into endothelial cells and create vessels as well (Ricci-Vitiani, et al. 2010, Wang, et
al. 2010). The five major types of vasculature are illustrated in Figure 1.2. For the studies
described in this thesis, I will focus mostly on angiogenesis and vasculogenic mimicry and these
will be discussed in further detail in the following sections.
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Figure 1.2 Types of Vasculature Present in Glioblastoma
A.) Vascular Co-option: The process where tumor cells hijack pre-existing brain vessels.
B.) Angiogenesis: Tumor cells stimulate pre-existing vessels to grow and expand within tumors
C.) Vasculogenesis: De novo formation of blood vessels from bone marrow derived progenitor
cells
D.) Vasculogenic Mimicry: Tumor cells act as vascular cells and form their own functional
vessels, independent of endothelial cells.
E.) GBM Stem Cell Endothelial Transdifferentiation: Glioma stem cells transdifferentiate into
endothelial cells and form vessels.
[Reproduced with permission from (Hardee and Zagzag 2012)]
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1.6 Tumor Vasculature: Angiogenesis

Angiogenesis is the process in which new blood vessels are generated. This is a normal
event that occurs during embryonic development, growth during puberty, wound healing, and
female reproductive organ maintenance (Bergers and Benjamin 2003). In general, endothelial
vessels are quiescent and these cells live for hundreds of days before being replaced
(Carmeliet, Mechanisms of angiogenesis and arteriogenesis 2000). However, in the occurrence
of an injury that disrupts these stable blood vessels, angiogenesis will be initiated. Vascular
endothelial growth factor A, VEGF-A, (will be referred to as VEGF in this writing) is one of the
main angiogenic factors that can promote blood vessel sprouting and formation (Pettersson, et
al. 2000). It binds to its main receptor, VEGFR-2, and sparks a signaling cascade that leads to
proliferation and survival of endothelial cells. The basic mechanism of physiological
angiogenesis is as follows (Kalluri 2003, Hofman and Chen 2010 , Bergers and Benjamin 2003,
Carmeliet 2000, Pettersson, et al. 2000):
1) Vasodilation (blood vessels swell)
2) Pericytes become loose and disconnect from the endothelial cells
3) Endothelial cells loosely connect to one another
4) Extracellular matrix is degraded by MMPs (metalloproteinases)
5.) Endothelial cells proliferate due to VEGF, basic fibroblast growth factor, epidermal growth
factor, or other angiogenic proteins
6.) Endothelial cells migrate towards angiogenic factors
7.) Blood vessels are formed and pericytes are recruited for vessel stability
Tumor angiogenesis is the process where host vasculature is recruited to the tumor and
stimulates the sprouting and development of those vessels within the tumor. Tumor
angiogenesis is essential for tumor growth, and appears to be the rate limiting step in tumor

9

development (Kalluri 2003, Bergers and Benjamin, Tumorigenesis and the Angiogenic Switch
2003). The process is very similar to physiological angiogenesis, but is much more dynamic and
new vessels are always evolving due to the hypoxic nature of a highly proliferating tumor
(Kalluri 2003, Hofman and Chen 2010 , Bergers and Benjamin 2003, Carmeliet 2000, Pettersson,
et al. 2000). Hypoxia induces the secretion of large amounts of VEGF, other angiogenic factors,
and MMPs which leads to the development of new blood vessels. This process is summarized in
Figure 1.3.
Tumor vessels do differ from normal tissue vessels in a few key ways (Kalluri 2003,
Hofman and Chen 2010 , Bergers and Benjamin 2003, Carmeliet 2000, Pettersson, et al. 2000).
First, these vessels are often over-dilated and thus much leakier than the normal vessels.
Second, tumor vessels are disorganized and do not have a well-structured morphology. Lastly,
the endothelial cells of tumors multiply and migrate at a high rate, which is very different from
the low turnover seen with normal endothelial cells.
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Figure 1.3 Tumor Angiogenesis
A) Quiescent Vessel. B) Pericytes detach and basement membrane is degraded. C) Endothelial
cells move toward angiogenic signal. D) Endothelial cells begin to divide in the direction of the
signal. E) Endothelial cells reach each other at both ends and bind to each other to create a
vessel. Pericytes may help guide the endothelial cells as well. [Reproduced with permission
from (Bergers and Benjamin 2003)]
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1.7 Tumor Vasculature: Vasculogenic Mimicry
Another phenomenon that is abundant in cancer, especially in glioblastoma, is a process
known as vasculogenic mimicry (VM). VM refers to the ability of tumor cells themselves to
create vasculature that can carry blood and nutrients throughout a tumor, independent of
endothelial cell angiogenesis (Maniotis, et al. 1999). VM was first discovered in 1999 in
melanoma, and was later found in breast, prostate, lung, ovarian, as well as many other
cancers (Maniotis, et al. 1999, Hendrix, et al. 2003). Last year, vasculogenic mimicry was also
identified in glioblastoma (El Hallani, et al. 2010).
VM shares various characteristics with vasculogenesis, a primitive, immature form of
angiogenesis (Maniotis, et al. 1999, Hendrix, et al. 2003). These vessels or “tumor cell lined
channels” are characterized by a tube like network consisting of many smaller vessels that are
perfused with red blood cells (Hendrix, et al. 2003). In angiogenesis, it is thought that there is a
progenitor cell that can differentiate into a more mature vascular cell. In relation to cancer, this
event is known as transdifferentiation, whereby a tumor cell differentiates into a type of cell
that is not of the cancer cell’s origin, in this case some type of vascular cell (Dong, et al. 2011,
Ricci-Vitiani, et al. 2010, Wang, et al. 2010). It has been shown that these tumor derived
channels express both tumor markers and some vascular (endothelial or pericyte) cell markers
(Hendrix, et al. 2003, El Hallani, et al. 2010, Ricci-Vitiani, et al. 2010, Wang, et al. 2010). A
synopsis of VM can be seen in Figure 1.4.
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Figure 1.4 Vascular Networks in Melanoma.
This is a cross section of a tumor depicting the complex network of channels and vessels that
persist throughout the tumor. The circular channels are endothelial derived vasculature, and
the orange and green channels together comprise the tumor derived vasculature. Blue cells
are tumor cells and red circles throughout the channels are red blood cells. [Reproduced with
permission from (Hendrix, et al. 2003)]
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1.8 Molecular Mechanisms Controlling Endothelial Cell Junctions
As previously mentioned, blood vessels consist of two major cell types; endothelial cells
and pericytes. These cells must form stable connections that allow the transport of blood to
the various tissues of the body. Simultaneously, these bonds between the cells also must be
flexible in order for the body to respond to certain stresses, such as wound healing or
inflammation [35-38]. Thus, the connections, or cell-cell junctions, must be tightly controlled by
molecular cues to allow vessel growth and permeability.
There are two important kinds of contact involved with endothelial cells; endothelial to
endothelial cell binding and endothelial to pericyte binding. The first is mediated by tight
junctions and adherens junctions (Figure 1.5) [35]. These contacts allow endothelial cells to
bind together and pass ions and signals laterally to one another. Additionally, the space
between the contacts can allow other cell types to pass through, such as leukocytes during
inflammation (Dejana 2004, Bazzoni and Dejana 2004, Dejana, Tournier-Lasserve and
Weinstein 2009, Vestweber 2008).
Vascular endothelial cadherin, or VE-cadherin, is a vital adhesion molecule that is
specific to endothelial cells and helps maintain and regulate these junctions (Dejana 2004,
Bazzoni and Dejana 2004, Dejana, Tournier-Lasserve and Weinstein 2009, Vestweber 2008,
Dejana, Orsenigo and Lampugnani 2008). Its expression is polarized, localizing to specific ends
of the cells. When VE-cadherin is bound to another VE-cadherin molecule on an adjacent cell,
endothelial cells tend to be quiescent and anchored in place. This information is transmitted
intracellularly by a well-established molecular complex, the cadherin/catenin complex (Dejana
2004, Bazzoni and Dejana 2004, Dejana, Tournier-Lasserve and Weinstein 2009, Vestweber
2008, Dejana, Orsenigo and Lampugnani 2008). When homophilic binding occurs between VEcadherin proteins on neighboring cells, it stabilizes the interaction between VE-cadherin and
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beta-catenin. Beta-catenin, in turn, is bound to alpha-catenin. Alpha- catenin is tethered to
actin filaments, thus giving the endothelial cells a physical link to one another and the
cytoskeleton. During tumor angiogenesis, tumor cells secrete large amounts of VEGF. VEGF
binds to its receptor, VEGFR-2, causing VE-cadherin to associate with VEGFR-2. This leads to a
phosphorylation cascade, whereby VE-cadherin and beta-catenin become phosphorylated,
resulting in the dissociation of the complex. At the physiological level, this leads to an increase
in vascular permeability and angiogenesis (Dejana 2004, Bazzoni and Dejana 2004, Dejana,
Tournier-Lasserve and Weinstein 2009, Vestweber 2008, Dejana, Orsenigo and Lampugnani
2008). A summary of this pathway can be seen in Figure 1.6.
In addition to endothelial-endothelial adhesion, endothelial to pericyte contact is
critical to maintain vessel stability and permeability. The cell adhesion molecule neural
cadherin (N-cadherin) is responsible for this kind of contact (Dejana 2004, Bazzoni and Dejana
2004). N-cadherin is expressed in neuronal cells, pericytes, cancer cells, and endothelial cells
(Quadri 2012, Cavallaro and Dejana 2011). N-cadherin is no different than other cadherins in its
ability to associate with beta-catenin, and when it is phosphorylated or cleaved, leads to
dissociation of the complex. N-cadherin does not localize to the adherens junctions, as VEcadherin does, but it is expressed throughout the membrane (Dejana, Orsenigo and
Lampugnani 2008, Cavallaro and Dejana 2011). Therefore, pericytes can bind to accessible
areas on the membrane of endothelial cells to support vessels and regulate permeability
(Quadri 2012, Cavallaro and Dejana 2011).
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Figure 1.5 Endothelial Junction Organization.
Endothelial cells are held together by tight and adherens junctions, mediated by VE-cadherin
among other proteins. Pericytes interact with and bind to endothelial cells through Ncadherin. [Reproduced with permission from (Dejana 2004)]
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Figure 1.6 VE-cadherin and Beta-Catenin Complex.
A.) Under stable vessel conditions, endothelial cells are held together by VE-cadherin. VE-cadherin is bound to beta-catenin
intracellularly, which is linked to the actin cytoskeleton through alpha-catenin. B.) In the presence of high amounts of VEGF,
VE-cadherin and Beta-catenin are phosphorylated, leading to a disruption of the complex and decreased vessel stability.
[Reproduced with permission from (Dejana, Orsenigo and Lampugnani 2008).]
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1.9 Statement of Thesis
The overall goal of the dissertation work outlined here was to provide new insights on
the development of vasculature in GBM, with a heavy emphasis on YKL-40 mediated
mechanisms. Glioblastoma is an extremely complicated disease, with the worst prognosis of all
the primary cancers. It is therefore critical that we search for novel avenues to treat this horrible
affliction. YKL-40 is an intriguing target, due to the fact that it is overexpressed in many cancers,
yet nothing is known about its function in relation to cancer progression. Thus, I wanted to
explore its role in GBM development and provide evidence that YKL-40 is a novel target.
In chapter 2, I uncovered some key roles that YKL-40 plays in GBM. Because GBM is
characterized by extreme vasculature and radioresistance, that was an excellent place to begin
unveiling YKL-40 mediated mechanisms in GBM. YKL-40 was shown to stimulate angiogenesis in
vitro and in vivo. Additionally, blockade of YKL-40 with a newly developed monoclonal anti-YKL40 antibody dramatically inhibited angiogenesis and prolonged the life of mice in our models.
Mechanistically, YKL-40 induced angiogenesis through the membrane proteins Syndecan-1 and
integrin αVβ5, which activated intracellular signaling through focal adhesion kinase and
extracellular related kinase 1 and 2. This, in turn, up-regulated the angiogenic factor vascular
endothelial growth factor (VEGF), increasing tumor angiogenesis. Moreover, YKL-40 conferred
radioresistance to GBM cells through the AKT survival pathway and inhibition of YKL-40
sensitized these cells to radiation induced cell death. This was the first study that provided
evidence of the feasibility and efficacy of YKL-40 as a therapeutic target (with the antibody) and
displayed some of the mechanisms in which YKL-40 promotes GBM progression.
In chapter 3, the phenomenon known as vasculogenic mimicry (VM), an alternative form
of tumor vascularization, was validated and characterized in glioblastoma. We demonstrated
that VM was created by mural-like tumor cells that could form functional vessels independent of
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endothelial cells. Additionally, we provided a phenotypic marker panel that defines these cells
unambiguously as mural-like VM forming cells. Lastly, we established that this mechanism of VM
formation is independent of VEGF. This is significant because current targeted therapies against
GBM inhibit VEGF-mediated vasculature, but ultimately fail in the clinic. Thus, VM could be an
attractive target to block blood flow and stunt tumor growth.
In chapter 4, using the information gathered from chapters 2 and 3, we further explored
the idea of YKL-40 as a vasculature promoting factor, illustrating that YKL-40 can contribute to
the development of mural-like cells lining angiogenic vessels. Not only do GBM tumors contain
both angiogenesis and VM, they also contain “mosaic” vessels comprising host endothelial cells
and tumor cells. Here, we describe a role for YKL-40 driving the mural-like phenotype of GBM
cells. Functionally, these cells act similarly to host pericytes, supporting cells that line the
outside of endothelial derived vessels. YKL-40 promotes cell to cell contacts in these mosaic
vessels by controlling the well-established catenin/cadherin pathway. Tumors lacking YKL-40
were hyperpermeable, and developed much slower than tumors with high YKL-40 levels.
Overall, YKL-40 plays a major role in vessel integrity and permeability, and tumors with high
YKL-40 exhibit a better blood supply network and progress much faster. Ultimately, blocking
YKL-40 could be an effective countermeasure against the primary forms of vasculature in GBM
and prolong human life considerably. It is my hope the knowledge gained by the research
outlined herein on the mechanism of action of YKL-40 will deepen our understanding of
glioblastoma as well as provide a suitable target for therapeutics against this deadly disease.
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CHAPTER 2
YKL-40 STIMULATES ANGIOGENESIS AND CONFERS RESISTANCE TO RADIATION IN
GLIOBLASTOMA
The work presented in this chapter was done in collaboration with Steve Scully, Michael Faibish,
Sherry L Taylor, Dennis Oh, Luis Moral, Wei Yan, and Brooke Bentley. Parts of this chapter are
taken from the original research article: Francescone RA, Scully S, Faibish M, Taylor SL, Oh D,
Moral L, Yan W, Bentley B, Shao R. Role of YKL-40 in the angiogenesis, radioresistance, and
progression of glioblastoma. J Biol Chem. 2011. Apr 29;286(17):15332-15343.
2.1 Introduction
Tumor angiogenesis, a process of new vasculature formation, is of paramount
importance in solid tumor development (Folkman and Klagsbrun 1987). The supply of new
blood vessels in tumors not only supports autonomous tumor proliferation but also aids in
removing accumulated waste from extensive metabolism that would normally induce necrosis.
A number of angiogenic factors such as VEGF, bFGF, and a recently identified secreted
glycoprotein YKL-40 (also known as human cartilage glycoprotein-39) have been known to play
critical roles in the development of the tumor vasculature (Shao, et al. 2009, Yan, Bentley and
Shao 2008, Dreyfuss, Johnson and Park 2009). Thus, they presumably function through
synergistic action to give rise to a robust angiogenic phenotype.
YKL-40, a member of the chitinase-like glycoprotein family, was first identified from the
medium of a human osteosarcoma cell line MG-63 (Johansen, Williamson, et al. 1992).
Structural analysis has demonstrated that YKL-40 contains highly conserved chitin-binding
domains; however it functionally lacks the ability to act as a chitinase because of a mutation of
an essential glutamic acid residue to leucine in the chitinase-3-like catalytic domain (Renkema,
et al. 1998, Fusetti, et al. 2003). While the physiological role of YKL-40 is not completely
understood, it is conceivable that YKL-40 is linked with proliferation of connective tissues and
activation of vascular endothelial cells (Recklies, White and Ling 2002, De Ceuninck, et al. 2001,
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Malinda, et al. 1999). Growing clinical evidence has indicated that aberrant expression of YKL40 is largely associated with the pathogenesis of a variety of human diseases. For example, YKL40 levels are elevated in the blood serum of patients with chronic inflammatory diseases such as
rheumatoid- and osteo-arthritis, hepatic fibrosis, and Asthma (Sharif, et al. 2006, Johansen,
Christoffersen, et al. 2000, Volck, et al. 2001, Kirkpatrick, et al. 1997, Létuvé, et al. 2008), which
is suggestive of its pathological function associated with extracellular matrix remodeling. Over
the past decade, mounting clinical studies have demonstrated a correlation of elevated serum
levels of YKL-40 with aggressive cancers and poorer survival in carcinomas of the breast, colon,
ovary, and brain (Pelloski, Mahajan, et al. 2005, Cintin, Johansen, et al. 1999, Cintin, Johansen,
et al. 2002, Hogdall, et al. 2003, Johansen, Christensen, et al. 2003, Jensen, Johansen and Price
2003, Bergmann, et al. 2005), suggesting that serum levels of YKL-40 serve as a diagnostic and
prognostic biomarker. Recently, we found that YKL-40 is capable of stimulating angiogenesis of
microvascular endothelial cells in breast cancer (Shao, et al. 2009). In addition, YKL-40-induced
angiogenesis is dependent on the interaction between membrane receptors syndecan-1 (Syn-1)
and integrin αvβ3. These findings have shed light onto the mechanisms through which YKL-40
prompts breast cancer development.
Vascular endothelial growth factor (VEGF) is believed to be a primary promoter of
angiogenesis (Yancopoulos, et al. 2000). VEGF binds to two tyrosine kinase membrane
receptors, VEGFR-1 (known as Flt-1) and VEGFR-2 (also named as Flk-1). Flk-1 acts as a primary
receptor mediating VEGF-induced angiogenesis (Millauer, et al. 1996, Neufeld, et al. 1999,
Prewett, et al. 1999). Upon the binding of VEGF, Flk-1 is activated by autophosphorylation of
specific tyrosine residues, followed by the binding and activation of Src or proteins containing a
Src homology domain 2 (Guo, et al. 1995). Consequently, these mediators activate multiple
downstream effectors, including FAK and MAPK (Abedi and Zachary 1997, Wheeler-Jones, et al.
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1997). Clinic evidence shows that elevated serum levels of VEGF are related to decreased
survival in patients with breast cancers and brain tumors (Ilhan, et al. 2009, Zhao, et al. 2004).
Glioblastoma is the most deadly and aggressive type of brain tumor with a median
survival time of 12-15 months. It is characterized by highly vascularized tumors and resistance
to radio/chemotherapy (Wen and Kesari 2008). YKL-40 is one of the most over-expressed
proteins in glioblastoma (Nigro, et al. 2005, Tanwar, Gilbert and Holland 2002, Lal, et al.
1999)and its level correlates with tumor radioresistance and short survival (Pelloski, et al. 2005).
Interestingly, elevated VEGF in glioblastoma is also associated with tumor angiogenesis (Bao, et
al. 2006, Pàez-Ribes, et al. 2009, Ido, et al. 2008). However, clinical trials testing an anti-VEGF
antibody Bevacizumab (Avastin) in recurrent glioblastoma show minimal overall benefit to
survival (Verhoeff, et al. 2009, Kreisl, et al. 2009). Consistent with these results, there is strong
evidence in murine models indicating that anti-VEGF therapy alone resulted in opposite
outcomes in which angiogenic and malignant tumors unexpectedly developed (Pàez-Ribes, et al.
2009, Ebos, et al. 2009), suggesting that other angiogenic factors may contribute to this evasive
mechanism. This hypothesis was partially supported by the evidence that blockade of VEGF via
siRNA gene knockdown up-regulates YKL-40 transcript (Saidi, et al. 2008). However, it remains
to be determined for the regulatory relationship between YKL-40 and VEGF, and substantial
molecular mechanisms underlying tumor radioresistance and angiogenesis, the hallmark of
aggressive glioblastomas. In this study, we found that YKL-40 up-regulated VEGF, and both
acted as potent angiogenic factors to exert synergistic effects on angiogenesis in the
establishment of tumor malignancy. Moreover, YKL-40 protected tumor cell death induced by γirradiation. Elucidation of YKL-40’s molecular mechanisms may give rise to considerable
promise to devising novel therapeutic strategies designed to target YKL-40 in concert with
traditional anti-VEGF therapy.
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2.2 Experimental Strategy
In this study, we found that YKL-40 up-regulated VEGF, and both acted as potent
angiogenic factors to exert synergistic effects on angiogenesis in the establishment of tumor
malignancy. Moreover, YKL-40 protected tumor cell death induced by γ-irradiation. Elucidation
of YKL-40’s molecular mechanisms may give rise to considerable promise to devising novel
therapeutic strategies designed to target YKL-40 in concert with traditional anti-VEGF therapy.

2.3 Results
2.3.1 YKL-40 regulates VEGF and both synergistically promote angiogenesis
Two brain tumor cell lines U87 and SNB-75 were utilized to investigate a functional role
of secreted angiogenic factors YKL-40 and VEGF in glioblastoma development. YKL-40 was
highly detectable in both cell lines at the protein and mRNA levels, while other cell lines did not
express YKL-40 or a low level of YKL-40. VEGF was expressed in those two brain tumor lines as
well as osteoblastoma cells MG-63 and colon cancer cells HCT-116 (Figure 2.1A). To validate
that these angiogenic factors are associated with tumor angiogenesis, each brain tumor cell line
was injected subcutaneously into SCID/Beige mice and tumors were monitored weekly for 8
weeks. Immunohistochemical (IHC) analysis showed strong expression of YKL-40 and VEGF, and
extensive positive staining of CD31, a marker of vascular endothelial cells, in xenografted tumors
(Figure 2.1B), suggesting that both YKL-40 and VEGF may contribute to tumor development
through a synergistic mechanism on the development of angiogenesis.
To dissect the relationship between YKL-40 and VEGF in tumor angiogenesis, we
employed a YKL-40 gene knockdown approach in U87 cells by a stable retroviral siRNA infection.
A noticeable gene blockade was obtained in the cells expressing YKL-40 siRNA1 (S1) (Figure
2.2A). Conversely, engineering YKL-40 siRNA2 (S2) into the cells did not result in a decrease of
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YKL-40 as compared to the control cells containing an empty vector (Figure 2.2A). S1 cells
displayed a corresponding reduction of VEGF, whereas S2 and control cell lines did not show
altered VEGF (Figure 2.2A), suggestive of a regulatory role of YKL-40 in VEGF expression. In
order to test the possibility that VEGF may also in turn regulate YKL-40 expression constituting a
positive feedback loop for vigorous angiogenesis, parental U87 cells were treated with a
neutralizing anti-VEGF antibody. Interestingly, the neutralization of VEGF activity with a short
time (24 hr) failed to decrease expression of YKL-40 or VEGF itself relative to IgG-treated cells
(Figure 2.2B); however, blockade of VEGF for a week noticeably induced YKL-40 expression
(Figure 2.2C). The results indicate that VEGF does not have the ability to regulate YKL-40
directly, but blocking VEGF for a long term up-regulates YKL-40. To assess angiogenic activities
of YKL-40 in vascular endothelial cells, human microvascular endothelial cells (HMVECs) were
engaged to measure tube formation on Matrigel, the assay that recapitulates vascular
angiogenic signature in vivo. U87 conditioned medium treated with an anti-VEGF antibody for
one week moderately suppressed tube formation by approximately 35% of IgG-treated tubes
(Figure 2.2C, compared with a strong inhibition below), suggestive of a compensatory role
played by YKL-40 in angiogenesis after the inhibition of VEGF. We next sought to determine the
effects of both YKL-40 and VEGF on angiogenesis. S1 medium drastically inhibited tubules by 5868% relative to the medium from S2 or control cells (Figure 2.2D). In order to firmly establish
the role of YKL-40 and VEGF in angiogenesis in vitro, neutralizing monoclonal antibodies against
VEGF and YKL-40 (mAY) were added to the conditioned medium of the U87 control cells for 16
hr. In line with YKL-40 gene knockdown, anti-VEGF antibody suppressed tubules by 57% and
mAY reduced tubules by 65% compared to IgG control (Figure 2.2D). Combined treatments with
the anti-VEGF antibody and YKL-40 siRNA or mAY strikingly suppressed tube formation by 88%
and 93% relative to controls, respectively. Collectively, these data suggest that YKL-40 may have
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a role in the regulation of VEGF expression, both of which collaborate to enhance angiogenesis,
and that blockade of VEGF induces YKL-40 expression.
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Figure 2.1 YKL-40 and VEGF are highly expressed in two glioblastoma cell lines and in both
cell line-induced vascular tumors
A. YKL-40 mRNA and protein levels, and VEGF mRNA levels were analyzed using RT-PCR and
Western blot in HMVEC, MG-63, HCT-116, U87 and SNB-75 cells. Actin and GAPDH were
used as loading controls for the Western blot and RT-PCR, respectively. B. U87 and SNB-75
cells were injected subcutaneously into SCID/Beige mice. CD31 staining of mouse endothelial
cells in both a U87 tumor and SNB-75 tumor demonstrated extensive vasculature throughout
the tumors. YKL-40 and VEGF were also highly expressed in these tumor samples. Inserts
indicate negative controls. Bar: 200 m.
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Figure 2.2 YKL-40 regulates VEGF expression and both enhance angiogenesis in vitro.
A. YKL-40 regulates VEGF expression. YKL-40 gene was knocked down in U87 cells using two
different siRNA constructs and YKL-40 and VEGF levels were detected using Western Blotting.
Actin was used as loading controls. C, S1, and S2 represent vector control, YKL-40 siRNA1, and
YKL-40 siRNA2, respectively. B. VEGF does not regulate YKL-40 directly. U87 cells were treated
with an anti-VEGF neutralizing antibody for 24 hrs, and VEGF and YKL-40 levels were tested
using RT-PCR and immunoblotting. C. Chronic blockade VEGF induces YKL-40. One week
following treatment with an anti-VEGF antibody, conditioned medium was tested for YKL-40
expression and also for tube formation of HMVECs. Cell lysates were tested for mRNA levels of
YKL-40 using RT-PCR. *P<0.05 compared with IgG control. n=3. D. YKL-40 and VEGF
synergistically increase tube formation. HMVECs were placed on Matrigel in the presence of
conditioned media collected from the U87 cells lines (top row) and allowed to grow for 16 hrs.
Additionally, HMVECs were also grown on Matrigel with media collected from control U87
cells pre-treated with anti-VEGF antibody, mAY, IgG (10 g/ml) or combination (bottom row).
Tubes were counted for each condition. *P< 0.05 compared with control or IgG group, and
+
P<0.05 compared with single treatment. n= 3.
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2.3.2 YKL-40 induces VEGF expression and angiogenesis through signaling activation of
integrin v5, Syn-1, FAK, and Erk
In an attempt to define the molecular mechanisms by which YKL-40 regulates VEGF, we focused
on signaling activation in U87 cells. Although membrane receptors specific for YKL-40 binding
are still unknown, we have demonstrated that YKL-40 triggers coupling of membrane receptor
syndecan-1 (Syn-1) and integrin v3 through binding to heparan sulfate of the ectodomains of
Syn-1 in HMVECs (Shao, et al. 2009). U87 cells expressed both Syn-1 and integrin v3 and
v5 (Figure 2.3). However, YKL-40 gene knockdown did not have an impact on the expression
of either receptor. To determine if YKL-40 induces the coordination of these receptors, we
utilized a co-immunoprecipitation approach followed by immunoblotting. We surprisingly found
that both control and S2 cells demonstrated a strong association of Syn-1 with integrin v,
whereas S1 cells were defective in their interaction (Figure 2.4A). In contrast, neither control
nor YKL-40 siRNA cells exhibited the interaction between Syn-1 and integrin v3 (Figure 2.4A).
These data provide strong evidence revealing the specificity of this signaling pathway that is
dependent on individual cell types. To further identify intracellular signaling pathways, we then
measured FAK, Erk-1 and Erk-2. An active level of pFAK397 was significantly reduced in S1 cells
relative to control cells (Figure 2.4B). Accordingly, pErk-1 and pErk-2 were decreased in S1 cells.
To validate this signaling pathway regulated by YKL-40, we neutralized YKL-40 activity
using mAY in the control cells. mAY disrupted the coupling between integrin v5 and Syn-1
from as early as 10 min to 60 min and this inhibition slightly diminished at 6 hr (Figure 2.4C).
Consistent with this inhibition, pFAK397, pErk-1, and pErk-2 were decreased by mAY, in which
pFAK397 displayed a trend to recovery from 30 min to 6 hr, whereas pErk-1 and pErk-2 recovered
at 6 hr. In order to determine if YKL-40 is able to rescue the signaling impaired in S1 cells, we
exposed these cells to recombinant YKL-40 and found that pFAK397 was notably increased from
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30 to 60 min; then slightly reduced (Figure 2.4D). Like mAY blockade, a delayed response of
pErk 1 and pErk 2 to YKL-40 stimulation was observed at 6 hr (Figure 2.4D), suggesting a
downstream signaling pathway from FAK to Erk. To ensure that prolonged treatment of S1 cells
with YKL-40 can restore VEGF production, these cells were exposed to recombinant YKL-40 for
24 hr. YKL-40 induced expression of pErk-1, pErk-2, and VEGF in a dose-dependent manner
(Figure 2.4D).
Next, to determine if the “outside-in” signaling pathway initiated by YKL-40 mediates
VEGF expression, we engaged a series of different inhibitors specific for individual signaling
mediators which include a small molecule PD98059 targeting MEK, and neutralizing antibodies
against YKL-40 (mAY), integrin v3 (LM609) and v5 (P1F6). Neutralization of integrin v5,
MEK or YKL-40 resulted in a reduction of pFAK397, pErk-1, pErk-2, and VEGF expression compared
to either IgG or DMSO-treated controls (Figure 2.4E). Interestingly, LM609 also moderately
inhibited VEGF expression, implicating that other factors may also utilize integrin v3 in the
induction of VEGF. Taken together, these results have established an action model for YKL-40 in
the regulation of VEGF, in which YKL-40 promotes the coordination of Syn-1 and integrin v5,
and induces intracellular signaling FAK, Erk-1, and Erk-2, leading to VEGF expression.
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Figure 2.3 Integrin αvβ5, αvβ3, and Syn-1 are expressed in U87 cell lines.
A. U87 cells were blocked with BSA for 45 minutes and then incubated with either anti-integrin αvβ5 (P1F6) or αvβ3 (LM609) monoclonal
antibodies for 45 minutes. Then the cells were incubated with anti-mouse FITC conjugated secondary antibodies and subjected to FACS
analysis. B. Expression of Syn-1 was determined by immunoblotting in the U87 YKL-40 knockdown and control cells. HMVECs were used as
a positive control.
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Figure 2.4 YKL-40 increases VEGF expression by signaling through integrin v5, Syn-1, FAK,
and Erk
A. YKL-40 signals through Syn-1 and integrin v5 but not integrin v3. Baseline
Immunoprecipitation of integrin 5 and 3 was performed on the U87 cell lysates, followed
by Western blotting against Syn-1. The bands of IgG were used as loading controls. B. YKL-40
knockdown decreases expression of pFAK and pErk. pFAK, total FAK, pErk-1, pErk-2, total Erk1, and Erk-2 protein levels were tested in the cells. pFAK, pErk 1 and 2 were quantified by
normalizing with total FAK, Erk 1 and 2, respectively. Control pFAK and pErk were set up as
one unit. C. Neutralization of YKL-40 by mAY inhibits YKL-40 signaling. U87 control cells
were treated with mAY (10 g/ml) from 10-360 min and then some of cell lysates were
immunoprecipated with an anti-integrin 5 antibody followed by immunoblotting against
Syn-1. The rest of lysates were subjected to immunoblotting using anti-pFAK, total FAK, pErk,
and total Erk antibodies. pFAK and pErk were quantified as described in B. D. Addition of
recombinant YKL-40 protein to S1 cells increases pFAK, pErk-1, pErk-2, and VEGF protein
levels. S1 cells were treated with YKL-40 (200 ng/ml) from 30-360 min. Cell lysates were
analyzed for expression of pFAK, total FAK, pErk, and total Erk followed by quantification of
pFAK and pErk as described in B. In addition, S1 cells were treated with 0, 50, 100, or 200
ng/mL of recombinant YKL-40 for 24 hrs. pErk, total Erk, and VEGF protein levels were tested
by western blotting. pErk 1, pErk 2, and VEGF were normalized with total Erk 1, Erk 2, and
actin, respectively. Each expression level without YKL-40 treatment was set up as one unit.
E. Inhibition of integrin v5, Erk, or YKL-40 results in reduced pFAK, pErk-1, pEkr-2, and VEGF
protein levels. Control U87 cells were treated with PD98059 (MEK inhibitor, 10 M) or a
monoclonal neutralizing antibody against either integrin v5 (P1F6), integrinv3 (LM609),
or YKL-40 (mAY) (10 g/ml) for 24 hrs. Media samples and cell lysates were collected and
western blotting was performed to determine pFAK, pErk-1, pErk-2, total FAK, Erk-1, Erk-2,
and VEGF protein levels. Actin was tested as a loading control. pFAK, pErk 1, pErk 2, and
VEGF were normalized with total FAK, Erk 1, Erk 2, and actin, respectively. Control IgG values
in each expression were set up as one unit.
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2.3.3 YKL-40 protects -irradiation-induced cell death in an AKT-dependent manner
It was established that serum levels of YKL-40 were elevated in glioblastoma patients treated
with radiation therapy (Tanwar, Gilbert and Holland 2002).

Furthermore, these elevated

concentrations positively correlated with cancer recurrence and poor survival, suggesting that
serum levels of YKL-40 serve as a prognostic biomarker (Hormigo, et al. 2006). To test the
hypothesis that -irradiation-induced YKL-40 protects tumor cell death, we monitored the levels
of YKL-40 in U87 cells exposed to -irradiation. Treatment of control cells with -irradiation
resulted in an increase of YKL-40 with the strongest induction at 10 Gy -irradiation (Figure 2.5A)
but not 20 Gy -irradiation (data not shown). In contrast, -irradiation was unable to markedly
induce YKL-40 expression in S1 cells. Although the control cells constantly expressed high levels
of VEGF, regardless of the treatment with different doses of -irradiation, S1 cells did show a
notable reduction in VEGF and exposure of the S1 cells with -irradiation failed to induce VEGF
dramatically, underscoring an important role of YKL-40 in the regulation of VEGF during
radiotherapy. Next, to test if YKL-40 acts as a survival factor in the radiation treatment, both
control and S1 cells were challenged with 10 Gy -irradiation for 48 hrs.

Control cells

experienced minimal cell death at 0 Gy and 10 Gy -irradiation (Figure 2.5B+C). However, the S1
cells suffered 25% and 35% cell death at 0 and 10 Gy -irradiation, respectively (Figure 2.5B+C),
both of which increased cell death approximately 2.5-3 fold greater than corresponding control
cells; demonstrating a survival function played by YKL-40. Given that YKL-40 controls VEGF
expression, we tested if VEGF mediates YKL-40-induced cell survival. A neutralizing anti-VEGF
antibody was engaged, but it did not influence cell death in the control cells treated with irradiation (Figure 2.5D and Figure 2.6A). These data indicate that YKL-40 protects -irradiationinduced cell death in a VEGF-independent manner.
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To explore a molecular mechanism underlying the cell survival, we focused on
expression of PI3K and AKT, the common signaling pathways mediating cell survival. Strikingly,
10 Gy -irradiation up-regulated pAKT by 50% in the control U87 cells, while the treatment
dramatically reduced expression of pAKT in the S1 cells compared to the levels after treatment
with or without -irradiation in the control cells (Figure 2.5E). Interestingly, while PI3K protein
levels were not altered in the cells exposed to -irradiation PI3K kinase activity was decreased
by 30% compared with controls when treatment of both -irradiation and YKL-40 siRNA (Figure
2.5E), suggesting that YKL-40 protects cell death induced by -irradiation at least partially
through regulation of the PI3K-AKT pathway. Consistent with the evidence that VEGF did not
mediate YKL-40-induced cell survival, neither AKT nor PI3K was altered in the inhibition of VEGF
(Figure 2.6B).

To further assess if -irradiation-induced YKL-40 consequently influences

endothelial cell angiogenesis, which recapitulates YKL-40-induced angiogenesis via a paracrine
fashion in vivo, we examined effects of conditioned media from the irradiated U87 cells on
tubules formed by HMVECs on Matrigel. Consistent with the earlier findings (Figure 2.2D),
conditioned medium of S1 cells decreased 50% of control tubules (Figure 2.5F). Markedly,
conditioned medium of U87 cells treated with -irradiation induced tubules by 60% relative to
non--irradiation-treated medium. But S1 cell medium treated with -irradiation suppressed
these tubules to the non-treated basal levels.

In sum, all the data demonstrate that YKL-40

induced by -irradiation prompts tumor cell survival through a PI3K-AKT pathway, and
concomitantly stimulates endothelial cell angiogenesis.
To further confirm the survival activity played by YKL-40 in radioresistance, we treated
U87 parental cells with mAY in exposure of 10 Gy irradiation for 96 hr. In line with the S1 and
control U87 data above, neutralization of YKL-40 activity led to 60% cell death compared with
40% cell death in the absence or presence of IgG after 10 Gy -irradiation (2.7), strengthening

34

the findings that YKL-40 protects -irradiation-induced cell death and that mAY may serve as a
powerful therapeutic tool to treat radioresistant cancer patients.
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Figure 2.5 YKL-40 protects U87 control cells from irradiation-induced death. A. YKL-40, but
not VEGF, is up-regulated with irradiation.
U87 control and S1 cells were exposed to 0, 3, 5, or 10 Gy irradiation and media samples were
collected 48 hrs after irradiation. A. YKL-40 and VEGF protein levels were tested by western
blotting. Actin was used as a loading control. B & C. U87 S1 cells are more susceptible to
irradiation. Both U87 control and S1 cells were plated and exposed to 0 or 10 Gy irradiation.
Forty-eight hrs later, the live/dead assay was employed to determine cell viability. The results
were then quantified. *, +P<0.05 compared to controls without irradiation and S1 without
irradiation, respectively. n = 3. D. VEGF does not mediate YKL-40-induced cell survival. U87
control cells were plated and exposed to 0 or 10 Gy irradiation in the absence or presence of
an anti-VEGF antibody. Forty-eight hrs later, the live/dead assay was employed to determine
cell viability. The results were then quantified. n = 3. E. YKL-40 regulates pAKT levels and PI3K
activity in cells exposed to-irradiation. Cell lysates were collected 48 hrs after 0 or 10 Gy
irradiation. pAKT, total AKT, and PI3K were tested by western blotting. The levels of pAKT
were normalized with total AKT and the control level of pAKT without irradiation treatment
was set up as one unit. F. Treatment of both irradiation and YKL-40 knockdown leads to
suppression of PI3K activity. U87 cells were exposed to irradiation for 48 hr and then lysed for
analysis of PI3K activity. The activity was normalized with a control level without irradiation as
one unit. P<0.05 compared with any group. n=3. G. Endothelial cell tube formation is
increased by irradiation of U87 cells, but decreased by YKL-40 siRNA. HMVECs were plated
onto Matrigel in the presence of conditioned media collected from U87 control and S1 cells
exposed to 0 or 10 Gy irradiation. Tubes were allowed to form for 16 hrs. The number of tubes
was counted for each condition. *P<0.05 compared to controls and +P<0.05 compared to 0 Gy
control, n=3.
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Figure 2.6 VEGF neutralization does not sensitize U87 parental cells to irradiation.
A. U87 cells were treated with either IgG or VEGF monoclonal antibody and subjected to 0 or 10 Gy of γ-irradiation. 48 hours later, the live
dead assay was performed and these representative pictures were taken. B. Cell lysates were collected 48 hrs after 0 or 10 Gy irradiation in
the absence or presence of an anti-VEGF antibody. pAKT, total AKT, and PI3K were tested by western blotting.
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Figure 2.7 A monoclonal neutralizing antibody against YKL-40 increases sensitivity of U87
cells to irradiation.
U87 Cells were treated with IgG, mAY, or neither of them (control) and then were exposed to
10 Gy irradiation. Ninety-six hrs later, the cells were subjected to the live/dead assay.
Representative images were exhibited for each condition (top) and then the number of live
and dead cells was quantified (bottom). *P<0.05 compared to control or IgG, n=3.
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2.3.4 YKL-40 promotes tumor growth, angiogenesis and metastasis in vivo
While the in vitro evidence established thus far has demonstrated that YKL-40 mainly controls
angiogenesis, we then sought to ascertain the vital role played by YKL-40 with respect to tumor
angiogenesis and progression in vivo. We performed two distinct mouse models for the study.
In the first model, we attempted to mimic a clinical trial for the treatment of GBM by
administering mAY into U87 xenografted mice from week 3 when these mice developed
palpable tumors. Mice were given either 5 mg/kg mAY or a monoclonal IgG as controls twice a
week for two more weeks prior to sacrifice. mAY treatment significantly inhibited tumor
formation as 50% of tumor volume was decreased compared with tumors developed from mice
treated with IgG (Figure 2.8A). In order to corroborate the in vitro data, we stained CD31
expression for angiogenesis in tumor samples and IHC analysis revealed that mAY markedly
reduced CD31 levels compared to IgG counterpart; as the staining intensity was 25% of the
control group (2.7B+C). Furthermore, in the analysis of ectopic tumor development, the mAY
reduced liver metastasis by 40%, whereas all IgG-treated control animals grew massive tumor
cells in the liver (Figure 2.8B+C). Neither IgG nor mAY-treated mice were found to contain
disseminating tumor cells in the lung (Figure 2.8B). These data strongly support the notion that
mAY can be used as a therapeutic agent targeting angiogenesis and metastasis in advanced
tumors.
In the second xenografted model, we injected U87 control and S1 cells into mice in
order to determine how YKL-40 gene knockdown would affect tumor development in vivo. As
demonstrated in Figure 2.8D, all the animals receiving U87 control cells began to form tumors
from week 4 and continued to develop exponentially large tumors until the mice were sacrificed
by week 7. Conversely, only one of the six mice injected with U87 S1 cells exhibited a two-week
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delayed tumor (Figure 2.8D, grey diamonds). Surprisingly, the remainder of these animals failed
to form tumors even in the observation period extended to 11 weeks. Subsequently, IHC
analysis of angiogenesis in all control tumors indicated strong staining of CD31 and VEGF (Figure
2.8E); whereas one S1 tumor sample showed weak expression of CD31 and VEGF (igure 2.9).
Furthermore, liver metastasis was identified in three of six control mice contrary to S1 mice in
which one of six individual liver samples harbored tumor cells (Figure 2.8E). Taken together,
these mouse models suggest that YKL-40 is associated with tumorigenesis, angiogenesis, and
metastasis.
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Figure 2.8 YKL-40 is associated with increased tumor development and angiogenesis in two
xenografted mouse models.
A. mAY reduces tumor volume. U87 parental cells were subcutaneously injected into
SCID/Beige mice and once tumors developed by week 3, the animals were treated with 5
mg/kg mAY or IgG by subcutaneous injection twice a week for 2 weeks. Mouse volume was
shown at the end of the treatment. B. Tumor angiogenesis and liver metastasis are reduced
with mAY treatment. IHC analysis of CD31 was performed on mouse tumor samples from the
IgG and mAY groups. H & E staining was performed on liver tissues from each group as well.
Bar: 200 m. C. Quantification of Part B was shown. *P<0.05 compared to controls, n=5. D.
YKL-40 S1 knockdown inhibits tumor formation. U87 control and S1 cells were
subcutaneously injected in SCID/Beige mice and observed for tumor development over 11
weeks. All control mice formed tumors within 7 weeks; whereas only 1 of 6 S1 mice formed
a tumor between week 7 and 9, and remainder of the mice did not form palpable tumors
over 11 weeks. Open circles represent control mice, triangles represent the only one S1
mouse that formed a tumor, and pink diamonds indicate the other five S1 mice. E. U87
control tumors express high levels of CD31 and VEGF. IHC of CD31 and VEGF was performed
on the tumor tissue of the U87 control mice. Liver metastasis was quantified as well for the
U87 control and S1 cells (staining images of tumor cells were not shown). Bar: 100 m.
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Figure 2.9 U87 YKL-40 siRNA xenograft tumor has reduced CD31 and VEGF expression.
Immunohistochemical analysis of U87 control and S1 xenograft tumors was performed.
CD31 and VEGF were stained in the tumor sections. Bars: 200 mm.
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2.3.5 Elevated expression of YKL-40 is associated with increased VEGF and poorer survival of
glioblastoma patients
We finally aimed to explore the relationship of YKL-40 with VEGF production, tumor
angiogenesis, and tumor malignancy in patients with glioblastomas. Tumor samples from 12
patients diagnosed with glioblastomas were utilized for expression of YKL-40 and VEGF by
immunoblotting. Given that variable levels of YKL-40 were observed in these specimens, we
classified each patient into two categories:

low YKL-40 expression (L) and high YKL-40

expression (H) (Figure 2.10A). An analysis of patient survival showed a median survival of 14.6
vs 5.9 months in these two groups, demonstrating that elevated YKL-40 positively correlated
with poor patient survival (Figure 2.10B). YKL-40 levels also appeared to correlate with VEGF
expression (Figure 2.10B). To validate the association of these angiogenic factor levels with
tumor angiogenesis, we stained these tumor samples for YKL-40, VEGF, and CD34 levels by IHC.
Agreed with the immunoblotting data, the higher the YKL-40 expression was, the higher the
VEGF expression and the more extensive the vessels appeared to be (Figure 2.11A). YKL-40
levels in the immunoblotting analysis were in parallel with YKL-40 expression analyzed by IHC
(Figure 2.11B), confirming the specificity of a polyclonal anti-YKL-40 antibody in recognizing YKL40 in tumors and also establishing these two sensitive assays for a diagnostic purpose.
Statistical analyses of YKL-40, VEGF, and CD34 expression displayed a trend toward positive
correlations based on these available samples (Figure 2.11B). Collectively, these human data
supported our hypothesis that YKL-40 plays a principal role in the regulation of VEGF, the strong
vasculature phenotype, and the tumor malignancy.
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Figure 2.10 YKL-40 and VEGF are over-expressed in glioblastoma patients with poorer
survival. A. YKL-40 and VEGF are expressed in glioblastoma patients.
Protein samples were isolated from 12 glioblastoma tumor specimens and subjected to
Western blotting. Actin was used as a loading control. MG63 osteosarcoma conditioned
medium was used as a positive control. Tumor samples were classified into two groups
based on YKL-40 intensity: L = low expression and H= high expression. Additionally, VEGF
was scored for band intensity as well: 0 = minimal level, 1 = low level, 2 = medium level, and
3 = high level of VEGF. Top row shows patient survival data. “>” indicates patients currently
live longer than these months. B. Elevated levels of YKL-40 are associated with decreased
patient survival and possibly increased VEGF expression. Left: comparison of YKL-40
expression groups (low and high levels, n=6/group) to average patient survival. Right:
comparison of YKL-40 expression to VEGF levels.
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Figure 2.11 YKL-40 levels appear to correlate with VEGF and CD34 levels.
A. Immunohistochemical analysis of low and high YKL-40 patient cases. Representative tumor
samples from low (L) or high (H) YKL-40 groups (Fig. 7) were stained for YKL-40, VEGF, and
CD34. Bar: 100m. B. Top: YKL-40 staining of IHC was semi-quantified with density (0-3
points) and intensity (0-3 points) scores as described in the Methods, and YKL-40 bands of
immunoblots (Fig. 7A) were analyzed based on intensity (0-3 points). The scores were then
subjected to a linear regression analysis followed by significance analysis. Bottom: VEGF was
semi-quantified based on staining density and intensity (0-6 points) and CD34 was scored by
overall staining density.
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2.4 Discussion
YKL-40 was recently identified as a potent angiogenic factor capable of inducing
endothelial cell angiogenesis in breast cancer, independent of VEGF (Shao, et al. 2009). Our
current study demonstrates for the first time the regulatory mechanisms of these two important
angiogenic factors in the malignancy of glioblastoma that is characterized by strong vascular
proliferation. We have identified that YKL-40 up-regulates VEGF and YKL-40-induced tumor
angiogenesis is at least partially dependent on VEGF by means of a multidisciplinary approach
including pharmacological and genetic methods, xenograft models in vivo, and human tumor
samples. In addition, YKL-40 induced by -irradiation is the key component responsible for
tumor radioresistance, independent of VEGF. mAY can block YKL-40-induced angiogenesis and
metastasis. These findings have provided substantial evidence to elucidate the phenomena
reported previously that serum and tissue levels of YKL-40 in glioblastomas are markedly
elevated and these increased levels positively correlate with radioresistance and shorter survival
(Nigro, et al. 2005, Hormigo, et al. 2006). Therefore, the current study not only provides
mechanistic insights into the angiogenic properties of glioblastoma; but also establishes YKL-40
as a tumor diagnostic and prognostic biomarker in tumor radioresistance as well as a novel
target for anti-angiogenic therapy.
With respect to the regulation of VEGF and angiogenesis, YKL-40 was found to induce
the collaboration of Syn-1 with integrin v5 and then elicit intracellular signaling cascades
through pFAK391 to MAP kinase. This action model is highly consistent with our previous findings
that the coupling of Syn-1 with integrinv3, in addition to pFAK861 to MAPK, mediates YKL-40induced angiogenic responses in vascular endothelial cells (Shao, et al. 2009). Interestingly,
LM609, the anti-integrin v3 antibody, was also found to partially reduce VEGF expression in
U87 cells, implying that other factors may also induce signal through integrin v3 to regulate
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VEGF. This hypothesis was supported by multiple lines of in vitro and in vivo evidence previously
(Hood, et al. 2003, Lorger, et al. 2009). For example, integrin v3 signaling was demonstrated
to constitutively up-regulate VEGF expression in MDA-MB-435 breast cancer cells implanted into
SCID mice (Lorger, et al. 2009). Indeed, we found that treatment of U87 cells with mAY alone
failed to fully block VEGF expression (Figure 2.4C) or tube formation induced by both YKL-40 and
VEGF (Figure 2.2D). Nevertheless, we demonstrate that YKL-40 plays a predominant role in the
regulation of VEGF and angiogenesis. In addition, our data highlight the notion that the
receptor cross-talk model is essential for the transduction of YKL-40 “outside-in” signaling into
the cells, in which divergent signaling mediators participate in distinct functions (Figure 2.12).
We found that -irradiation induced YKL-40 expression which not only protected tumor
cell death, but also elicited endothelial cell angiogenesis in a paracrine fashion.

This YKL-40-

induced tumor cell survival was independent of VEGF, a factor that mediates endothelial cell
survival (Zhang, et al. 2010). However, this survival activity was through PI3K-AKT activation, a
common pathway which mediates survival of multiple types of cells (Chetty, et al. 2010, Inoue
and Meyer 2008). Consistent with our results, MAPK and AKT were reported to mediate YKL-40induced survival in tumor cells and mitogenic signaling in connective tissue cells (Recklies, White
and Ling 2002, Li, Kim and Waldman 2009). In addition, IHC analysis of glioblastomas indicated
that elevated expression of YKL-40 correlated with expression levels of pAKT and pMAPK in
poorer response of those patients to radiotherapy (Pelloski, Mahajan, et al. 2005, Pelloski, Lin,
et al. 2006). Therefore, our new data in context with others offered substantial insight into
radioresistance of glioblastomas that express increased levels of YKL-40 and demonstrate poor
prognosis (Figure 2.12).
mAY has been characterized in neutralizing YKL-40’s activities (Faibish et al. manuscript
submitted). Here, mAY displays the capability of blocking tumor angiogenesis and growth in vivo
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but failed to resemble the inhibitory extent of YKL-40 gene knockdown that completely
abolished the tumor development. The discrepancy may be attributed to different settings on
YKL-40 inhibition, in which mAY targets palpable tumors contrary to the siRNA approach that
genetically decreases YKL-40 levels in the tumor cells.

We also interestingly found that

subcutaneous injection with U87 cells gave rise to liver metastasis but not lung metastasis,
which is different from metastases of other tumor cells that disseminated to the lung and other
organs (Minn, et al. 2005, Richert, et al. 2005, Yan and Shao 2006). The inconsistency may be
due to the differences in administration methods of xenotransplants, invasiveness of tumor
cells, and tumor microenvironment that predisposes them to residing in specific sites.
Nonetheless, our data demonstrate that blockade of YKL-40 expression or activity suppresses
tumor growth, angiogenesis, and metastasis.

Moreover, the results also implicate the

therapeutic utility of mAY in the future clinical treatment.
Both immunoblotting and IHC analyses on twelve cases of glioblastomas revealed that
half of these samples express strong YKL-40, the high population of which is consistent with the
data documented in literature (Pelloski, Mahajan, et al. 2005, Tanwar, Gilbert and Holland
2002). In addition, these elevated expression levels of YKL-40 positively correlate with poorer
survival. The results demonstrate that these two tests can serve as diagnostic and/or prognostic
tools for predicting the outcomes of the disease. A more detailed epidemiological analysis of
YKL-40, VEGF, and CD34 with a large population will be essential for establishing that YKL-40 has
utility as a target for anti-angiogenic intervention in patients.
Insufficient anti-angiogenic therapy in glioblastoma patients has recently received
considerable attention because the benefits of these agents such as the anti-VEGF antibody
bevacizumab appear to be transitory (Verhoeff, et al. 2009, Wick, et al. 2010). These effects
may be due to drug resistance, tumor re-growth, and rapid vasculature recovery once the
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therapy is terminated. In agreement with these clinical trials, xenografted tumor models
provided convincing evidence demonstrating conflicting outcomes of anti-VEGF treatment,
including extensive revascularization, increased invasiveness, and ectopic dissemination (PàezRibes, et al. 2009, Casanovas, et al. 2005). In line with this evidence, a short-term therapy with
sunitnib (VEGF receptor kinase inhibitor) and SU11248 (VEGF and PDGF receptor kinase
inhibitor) accelerated local tumor invasion and multiple distant metastases after intravenous
injection of tumor cells or removal of primary tumors (Ebos, et al. 2009). Immediate adaptation
to the anti-angiogenic therapies is believed to be associated with the angiogenic switch by which
tumors undergo robust revascularization and malignant transformation. Our data showing the
up-regulation of YKL-40 following a long course of anti-VEGF treatment strongly suggests that
YKL-40 may play an angiogenic role in the resistance of enduring anti-VEGF therapy. This
assumption was also supported by a study of VEGF gene knockdown in U87 cells that expressed
elevated YKL-40 compared to control cells (Saidi, et al. 2008).

Therefore, an alternative

neutralization of YKL-40 should be taken into account in the clinical setting for the possible
elimination of this angiogenic rebound. A putative model has been illustrated demonstrating
the enhanced tumor angiogenesis associated with YKL-40 (Figure 2.12). YKL-40 acts as an
independent angiogenic factor and simultaneously up-regulates VEGF expression; thereby giving
rise to a synergistic impact on vascularization. In addition, tumors can rebound upon anti-VEGF
treatment alone because of up-regulation of YKL-40 by decreased VEGF. Although molecular
mechanisms underlying the induction of YKL-40 are still elusive, the levels of VEGF may be ratelimiting for YKL-40 regulation, possibly constituting a negative feedback loop. Thus, targeting
both YKL-40 and VEGF could be an efficacious regimen in concert with radiotherapy to
eventually eradicate this deadly disease.
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In summary, our findings demonstrate the angiogenic signature for YKL-40 in a vascular
phenotype of glioblastoma, the hallmark of tumor invasiveness. YKL-40 can not only induce
angiogenesis as an independent angiogenic factor, but also has the ability to stimulate VEGF
expression, resulting in synergistic effects on angiogenesis.

In addition, YKL-40 acts an

important component to mediate angiogenic rebound induced by anti-VEGF treatment as well
as tumor radioresistance.

Therefore, combined therapies including anti-YKL-40 and other

traditional anti-angiogenic agents together with chemo/radiation therapy warrant further
clinical investigation.
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Figure 2.12 A hypothetical scheme elucidating YKL-40-induced angiogenesis of glioblastoma,
partially dependent on VEGF.
YKL-40 up-regulates VEGF, both of which synergistically induce endothelial cell angiogenesis,
and YKL-40 also has the ability to directly promote angiogenesis as described previously (Shao,
et al. 2009). Constant inhibition of VEGF leads to up-regulation of YKL-40 that may stimulate
rapid vascular recovery and tumor re-growth, which contributes to anti-VEGF resistance and
evasive mechanisms for the tumor malignancy. In addition, -irradiation induces YKL-40
expression that increases tumor cell survival and also promotes endothelial cell angiogenesis,
leading to resistance to radiation therapy.
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2.5 Materials and Methods
2.5.1 Cell Culture
U87 cells (ATCC, Manassas, VA) and SNB-75 cells (NCI, Frederick, MD) were grown in DMEM
supplemented with 10% FBS and penicillin/streptomycin. HMVECs were grown in EBM-2 (Lonza,
Allendale, NJ) supplemented with 5 µg/ml hydrocortisone, 5 µg/ml insulin, 10 ng/ml hEGF, 10%
FBS, and penicillin/streptomycin.

2.5.2 RT-PCR

Total RNA from cells was extracted with Tri-reagent (Molecular Research Inc, Cincinnati, OH).
RNA concentration and purity were determined spectrophotometrically (A260/280). cDNAs
with poly A tails were subsequently synthesized through a reverse transcriptional reaction in the
presence of 15-oligo (dT) (Promega, Madison, WI). A fragment of VEGF and GAPDH DNA was
synthesized by a polymerase chain reaction with sense primer 5’-CTTTCTGCTGTCTTGGGTGC-3’
and antisense primer 5’- GTGCTGTAGGAAGCTCATCTCTCC-3’, and sense primer 5’-

2.5.3 Immunoprecipitation and immunoblotting

Cell lysate samples were processed as described previously (Shao, et al. 2009). Briefly, cell
lysates were then incubated with either an anti-integrin 5 or integrin 3 antibody (Chemicon
International, Temecula, CA) at 40C overnight followed by incubation with protein A sepharose
beads at 40C for 4 hr. The immunocomplex was extensively washed and the samples were
subjected to running SDS-PAGE. PVDF membranes were incubated with one of a series of
primary antibodies against YKL-40, VEGF (Sigma St. Louis, MO), Syn-1 (Santa Cruz Biotechnology,
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Santa Cruz, CA), pFAK397 (Biosource, Camarillo, CA), FAK, pErk, Erk (Santa Cruz), pAKT and AKT
(Cell Signaling, Beverly, MA), PI3K (Upstate Biotech, Lake Placid, NY), or actin (Sigma).
Membranes were then incubated with goat anti-mouse or anti-rabbit secondary antibodies
(Jackson Lab, Bar Harbor, Maine). Specific signals were

detected by

enhanced

chemiluminescence (VWR, Rockford, IL).

2.5.4 YKL-40 Gene knockdown
DNA oligos (19 bp) specifically targeting N-terminal (siRNA 1) or C-terminal (siRNA 2) region of
YKL-40, were selected and then templates (64 oligo nucleotides) containing these oligos were
subcloned into a retroviral pSUPER-puro-vector (OligoEngine, Seattle, WA). 293T retroviral
packaging cells were transfected with pSUPER siRNA constructs in the presence of pCL 10A1
vector using Fugene 6 (Roche, Indianapolis, IN). Forty-eight hours after transfection, the
supernatant was harvested and filtered through 0.45-m pore size filter and then the viral
medium was used to infect U87 cells. Selection with 1 g/ml of puromycin was started 48 hr
after infection and the puromycin-resistant cell populations were used for subsequent studies.

2.5.5 Tube formation assays
Human microvascular endothelial cells (HMVECs) (1 x 104cells) were transferred onto 96-well
Matrigel (BD Bioscience, San Jose, CA) in the presence of conditioned medium of tumor cells
with or without neutralizing antibody treatments. After 16 hours of incubation, tube-forming
structures were analyzed. Images were analyzed with an inverted microscope. Averages of
tubules were calculated from three fields in each sample.
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2.5.6 Irradiation of Cells and Live/Dead Assay

U87 cell lines were exposed to 0-10 Gy -irradiation from a radioactive Cesium source. To assay
cell viability, the Live/Dead Assay (Invitrogen, Carlsbad, CA) was employed. Briefly, 48 or 96
hours after -irradiation, cells were incubated with the Live/Dead mixture (calcein AM and
ethidium homodimer) to assess the number of live and dead cells. Fluorescent images of live
(green) and dead (red) cells were analyzed. The percentages of live and dead cells were
quantified.

2.5.7 PI3K kinase activity

Freshly isolated cell lysates were subjected to measuring kinase activity according to the
manufacture’s instruction of a kit (Millipore Inc. Bedford, MA).

2.5.8 Tumor xenografts in mice

All animal experiments were performed under the approval of Institutional Animal Care and Use
Committee of the University of Massachusetts. SCID/Beige mice were subcutaneously injected
with U87 (5-7.5 x 106) or SNB-75 (5 x 106) cells in 0.2 ml of PBS. At week 3 when mice developed
palpable tumors, mice received either a mouse monoclonal anti-YKL-40 antibody (mAY, 5 mg/kg
body weight) or mouse IgG (5 mg/kg) by subcutaneous injection twice a week for 2 weeks.
Tumor growth from these injected cells was monitored weekly for 5 weeks before the animals
were humanely sacrificed. Tumors were measured and tumor volume was calculated as follows:
volume = length x width2 x 0.52.
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2.5.9 Immunohistochemistry

Paraffin-embedded or frozen tumor tissues were cut to 6 m thickness and processed for
immunohistochemical analysis. In brief, samples were incubated with 3% H2O2 for 30 min to
block endogenous peroxidase activity, followed by incubation with blocking buffer containing
10% goat serum for 1 hr. The samples then were incubated at room temperature for 2 hr with
monoclonal rat anti-CD31 (1: 50, BD Pharmingen, San Diego, CA) and mouse anti-CD34 (1:200)
antibodies (Dako Inc, Carpentaria, CA), or rabbit polyclonal anti-VEGF (1:100, Santa Cruz) and
anti-YKL-40 (1:400). Goat anti-rat, mouse or rabbit secondary antibodies (1: 100, Dako Inc)
conjugated to HRP were added for one hr. Finally, DAB substrate (Dako Inc) was introduced for
several minutes and after washing, methyl green was used for counterstaining.

2.5.10 Human glioblastoma samples and IHC data analysis

The study of brain tumor samples was approved by Baystate Medical Center Institutional Review
Board. YKL-40 and VEGF staining was evaluated as combined scores of percent and intensity of
positive staining cells as following 1) percent: no staining is 0 points; <10% of cells stained is 1
point; 11-50% of cells stained is 2 points; and >50% of cells stained is 3 points; 2) intensity: no
staining is 0 points, weak staining is 1 point, moderate staining is 2 points and strong staining is
3 points. Thus, the valid range of scores was 0 to 6. CD34 density was quantified by an NIH
image analysis program.
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CHAPTER 3
MECHANISMS OF VASCULOGENIC MIMICRY IN GBM

The work presented in this chapter is part of an original research article: Francescone R, Scully S,
Bentley B, Yan W, Taylor SL, Oh D, Moral L, Shao R. Glioblastoma-derived tumor cells induce
vasculogenic mimicry through Flk-1 protein activation. J Biol Chem. 2012 Jul 13;287(29):2482124831.
3.1 Introduction
Glioblastoma (GBM) is an extremely aggressive brain tumor with a median survival of
approximately 12 months, irrespective of surgical resection and post-operative adjuvant
radio/chemotherapy (Wen and Kesari 2008). More than 70% of patients with GBM succumb to
the disease in 2 years and fewer than 10% are alive 5 years following initial diagnosis (Norden,
Drappatz and Wen 2009). Aggressiveness of this disease is characterized by strong vascular
proliferation which is highly correlated with the malignancy of GBM. Thus, most of the current
chemotherapies against GBM aim at vascular endothelial cells that orchestrate a significant
component of blood vessels (Nghiemphu, et al. 2009). However, it has been increasingly
documented that an anti-angiogenic monotherapy did not give rise to a promise for
improvement of patient overall survival, as drug resistance or angiogenic rebound occurs once
the treatment is terminated (Bergers and Hanahan 2008, Ellis and Hicklin 2008). For example,
clinical trials using a neutralizing anti-VEGF antibody (Bevacizumab, also named Avastin) in
recurrent GBMs revealed minimal benefit to patient survival (Bergers and Hanahan 2008,
Verhoeff, et al. 2009, Kreisl, et al. 2009). Consistent with clinical evidence, the anti-angiogenic
preclinical studies using animal models reported conflicting outcomes in which malignant
tumors unexpectedly developed (Ebos, et al. 2009, Pàez-Ribes, et al. 2009), implicating that
escape mechanisms may account for the malignancy.
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Recently, a number of research groups have demonstrated that vasculogenic mimicry
(VM), an alternative vascular mechanism, contributes a central role to the vascularization of
GBM in which tumor cells participate (Yue and Chen 2005, El Hallani, et al. 2010, Liu, et al.
2011). Growing evidence suggests that this matrix-embedded, blood-perfused microvasculature
renders tumor progression independent of endothelial cell angiogenesis (Maniotis, et al. 1999,
Folberg and Maniotis 2004). In addition, this VM is believed to be at least partially ascribed to
the multipotency of glioblastoma stem cells (GSCs) capable of transdifferentiation into vascular
non-endothelial cells (Ping and Bian 2011, Chen, et al. 2012). Furthermore, these studies
suggest that transdifferentiation of GSCs into mural-like tumor cells enable these vascular cells
to constitute blood-perfused channels, whereas endothelial cells induce angiogenesis in GBM.
An angiogenic factor VEGF is appreciated to evoke vascular endothelial cell angiogenesis
mainly through binding its membrane-bound receptors such as VEGF receptor 1/Flt-1 and VEGF
receptor 2/Fms-like tyrosine kinase-1 or kinase domain receptor (Flk-1/KDR) (Neufeld, et al.
1999, Yancopoulos, Klagsbrun and Folkman 1998). Flk-1 is the earliest differentiation marker for
endothelial cells and blood cells (Eichmann, et al. 1997, Shalaby, et al. 1995). Expression of Flk-1
in the adult is restricted to endothelial cells and transiently up-regulated during angiogenesis
(Neufeld, et al. 1999). Deletion of Flk-1 gene in mice results in embryonic lethality owing to the
lack of hematopoietic and endothelial lineage development (Shalaby, et al. 1995, Fong, et al.
1995). Once binding with VEGF, Flk-1 undergoes autophosphorylation of tyrosine residues
located in an intracellular kinase domain and subsequently activates multiple intracellular
signaling cascades such as focal adhesion kinase (FAK) and MAP kinase activation, leading to
endothelial cell angiogenesis (e.g. cell proliferation, migration and tube formation) (Yan, Bentley
and Shao 2008, Sun, et al. 2005).

Interestingly, previous studies showed that

transdifferentiation of embryonic stem cells into vascular endothelial cells and mural cells
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required expression of Flk-1 (Yamashita J, et al. 2000, Yang L 2008, Taura, et al. 2009). However,
it is largely unknown whether Flk-1 plays an essential role in the development of VM.

3.2 Experimental Strategy
Here we take advantage of GBM-derived tumor cell lines capable of developing VM to
investigate a role of Flk-1 in the vasculogenesis of GBM. Deciphering the molecular mechanisms
will offer considerable value for devising novel therapeutic regimen targeting non-endothelial
vascular proliferation in concert with current anti-angiogenic therapy.

3.3 Results
3.3.1 Identification of Vasculogenic Mimicry in Human Glioblastoma Cases
To determine if VM is present in GBM, we examined tumor samples from 11 patients
with GBM. Hematoxylin and eosin (H & E) showed a vascular pattern spread throughout the
majority of the tumor sections of 7 of 11 tumors and periodic acid-Schiff (PAS) staining of
vascular basement membrane revealed extensive blood-perfused channels, most of which
harbored vascular cells that displayed a torturous phenotype dissimilar to endothelial cells
(Figure 3.1A+B). Two of the other tumors contained a minimal level of vascular channels, while
the final two were avascular. To determine if these vascular channels are comprised of mural
cells, we utilized an immunohistochemical (IHC) approach by staining the samples with smooth
muscle alpha actin (SMa) and platelet-derived growth factor receptor (PDGFR), both of which
are vascular pericyte markers. A number of these vessels exhibited strong staining of both SMa
and PDGFR (Figure 3.1C+D). In a dual staining analysis of SMa and CD31, a vascular endothelial
cell marker, we found that some vessels contained endothelial cells and others consisted of
SMa-positive cells (Figure 3.1E). In addition, IHC analysis indicated that these mural cell-
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associated vessels were positive for Flk-1 (Figure 3.1F). To validate that these mural-like tumor
cells express Flk-1, we performed a dual immunofluorescent assay and found that a significant
component of the vascular channels co-expressed SMa with Flk-1 (Figure 3.1G), but not with
CD31 (Figure 3.1H). These data demonstrate that VM present in GBM is principally comprised of
mural cells that express Flk-1.
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Figure 3.1 Extensive tumor cell-associated, blood-perfused channels co-express SMa, PDGFR, and Flk-1 in GBMs.
Tumor specimens were subjected to staining of PAS (A), IHC of SMa (B), PDGFR (C), NG2 (D), SMa and CD31 (E), Flk-1 (F),
and immunofluorescent co-staining of SMa with Flk-1 (G), and SMa with CD31 (H). In A, arrows represent tumor cellassociated vascular channels in which blood cells are located (thick vessel walls); whereas arrow heads indicate endothelial
cell-associated vessels (thin vessel walls). In E, an arrow head indicates CD31-positive vessels. In G, vessels were strongly
positive for Flk-1 and SMa, whereas in H, a few vessels expressed CD31. Bars: 100m.

61

3.3.2 GBM Cells Possess a Mural-like Phenotype
To test our hypothesis that tumor cells act as vascular mural-like cells to participate in
VM, we investigated two glioblastoma tumor cell lines: U87 cells and GSDCs that were
established from patients with GBM. We performed immunoblotting to assess expression of
mural and endothelial cell markers. Both tumor lines U87 and GSDCs expressed stronger Flk-1
than that observed in HMVECs (Figure 3.2A). Contrary to HMVECs that express a barely
detectable level of SMa, U87 cells and GSDCs expressed a higher level of SMa.
Immunocytochemistry analysis unveiled the same expression pattern of Flk-1 and SMa as the
immunoblotting results (Figure 3.2A+B).

However, it was notable that both U87 cells and

GSDCs, in contrast to HMVECs, did not express endothelial cell-specific markers VE-cad, CD31,
Tie1 or Tie2, demonstrating that GSDCs are distinct from endothelial cells. U87 cells and GSDCs
expressed higher N-cad than did HMVECs, consistent with previous reports that vascular
endothelial cells also express N-cad in addition to VE-cad (Paik, et al. 2004, Luo, et al. 2006). In
order to confirm that this mural cell expression pattern was not just an artifact of one particular
patient-derived cell line, a second patient-derived cell line, GSDC-2, was created. GSDC-2 also
showed a nearly identical expression pattern as GSDCs (Figure 3.3A+B), suggesting that this
mural marker expression is a common characteristic of GBM cells.
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Figure 3.2 U87 cells and GSDCs express SMa and Flk-1, but not endothelial cell
markers.
A. Cell lysates of U87 cells, GSDCs, MDA-MB-231 cells and HMVECs were analyzed by
immunoblotting against Flk-1, SMa, VE-cad, CD31, Tie1, Tie2, N-cad, and actin. MDAMB-231 cells were used as a negative control. B. These cells were also used for
immunocytochemistry staining of SMa, Flk-1, and VE-cad. DAPI is nuclear staining.
Bars: 50 m.
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Figure 3.3 A second GBM patient derived cell line, GSDC-2, has a similar molecular and
functional profile as GSDC.
A. Western blot analysis of mural and endothelial markers. MDA-MB-231 cellswere used as
a negative control and HMVEC was a positive control for endothelial markers. Actin is a
loading control. B. Immunocytochemical analysis of GSDC-2 for the expression of Flk-1,
SMa, and VE-cadherin. C. Functional analysis of tube formation of GSDC-2. GSDC-2 were
treated with an anti-VEGF antibody (Bevacizumab, Beva.) (10 μg/ml) or SU1498, a Flk-1
inhibitor, (12.5 μM). Tubules were quantified. n=4.*P<0.05 compared with controls or
DMSO treatment.
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3.3.3 GBM Cells Have in vitro Vasculogenic Activity Dependent on Flk-1

Should U87 cells and GSDCs truly represent cells capable of developing vascular
channels, they might possess the vasculogenic activity as do endothelial cells (Shao and Guo
2004, Francescone, Faibish and Shao 2011). To test this hypothesis, we performed a tube
formation assay that commonly recapitulates the ability of endothelial cells to develop
vasculature in vitro. U87 cells and GSDCs formed a capillary phenotype on Matrigel in a cell
number-dependent manner (Figure 3.4A+B). To evaluate if this vascular event is dependent on
Flk-1 as expressed by mural cells (Figure 3.1) in GBM, we employed a Flk-1 kinase inhibitor
SU1498. Treatment with SU1498 inhibited the ability of both cells to induce capillary-like
structure by approximately 72-80% relative to controls (Figure 3.4C+D). To provide additional
genetic evidence that Flk-1 is important for vasculogenic function, we used an Flk-1 shRNA gene
knockdown approach. Suppression of Flk-1 was associated with a corresponding reduction in
SMa expression and tube formation as tubules were decreased by 80% of control tubules
(Figure 3.4E). These findings were also validated with the GSDC-2 cell line derived from another
patient (Figure 3.3C). In all the tube formation assays, treatment of either SU1498 or Flk-1 gene
knockdown did not result in cell growth arrest or cell death (Figure 3.5).
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Figure 3.4 U87 cells and GSDCs are able to induce vascular tube formation, the process
dependent on Flk-1.
A. Different cell numbers of U87 cells and GSDCs were cultured on Matrigel for tube formation.
HMVECs served as a positive control. n=3. B. The tubules formed by these cells were
quantified, demonstrating a cell number-dependent relationship. C. Tube formation was
performed overnight with U87 cells and GSDCs (2 x 104) in the presence of SU1498 (12.5 M).
D. Tubules were quantified. n=4. *P<0.05 compared with controls or DMSO treatment. E.
U87 cells were used to knock down Flk-1 gene. Cell lysates were collected for detection of Flk1, SMa and actin by immunoblotting. Cells carrying scrambled RNA GFP-vector or shFlk-1 RNA
GFP-vector were analyzed for tube formation under a florescence microscope followed by
quantification. n=3. *P<0.05 compared with a control.
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Figure 3.5 Flk-1 Inhibition does not cause cell death or impair growth of GBM cells.
GSDCs were either treated with control shRNA, Flk-1 shRNA, DMSO, or SU1498 (12.5 µM). 2
days later, cells were subjected to the Live/Dead Assay (Invitrogen) to measure cell death.
Green indicates live cells, as stained by Calcein AM, while red indicates dead cells, as stained
by ethidium homodimer (the top panel). Corresponding phase contrast pictures were shown
(the middle panel). Quantification of the fraction of living and dead cells for each treatment
group. N= 3, *P >0.05 (the bottom panel).
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3.3.4 Flk-1 Mediated VM is Independent of Vascular Endothelial Growth Factor
Next, we determined if this Flk-1-mediated vascular activity requires VEGF. We treated
these tumor cells with an anti-VEGF neutralizing antibody Bevacizumab in the tube formation.
As tested earlier, both U87 cells and GSDCs decreased the ability to develop tubules in the
presence of SU1498. In contrast, they did not display dysfunction of the vascular formation
once Bevacizumab was added (Figure 3.6A + Figure 3.3C). Accordingly, expression of SMa in
these cells was reduced by SU1498 but not by Bevacizumab, indicative of a VEGF-independent
event (Figure 3.6B). Regardless of higher expression of VEGF by U87 cells and GSDCs than that
by HMVECs, this vasculogenic capability of these tumor cells was distinct from the angiogenic
signature of vascular endothelial cells that highly responded to Bevacizumab in the development
of tubules (Figure 3.6C).
To further validate that Flk-1-mediated vasculogenesis does not require VEGF, we
stimulated U87 cells with VEGF in the tube formation assay. Exposure of both U87 control cells
and the cells expressing Flk-1 shRNA to VEGF did not alter vascular development, as VEGF did
not either enhance vascularization in the control cells or rescue the impaired capability of tube
formation in Flk-1 shRNA cells (Figure 3.6D). These data support the notion that Flk-1-mediated
VM is independent of VEGF.
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Figure 3.6 Flk-1-mediated vasculogenesis is independent of VEGF.
A. U87 cells and GSDCs were used for tube formation in the presence of an anti-VEGF antibody (Bevacizumab, Beva.) (10 g/ml) or SU1498
(12.5 M). Tubules were quantified. n=4. *P<0.05 compared with controls or DMSO treatment. B. U87 cells were treated with Beva (10
g/ml) or SU1498 (12.5 M) for 24 hr and cell lysates were subjected to immunoblotting against SMa and actin followed by quantification.
C. HMVECs were stimulated with VEGF (10 ng/ml) on Matrigel in the presence of Beva (10 g/ml). Data were quantified. n=4. *,+P<0.05
compared with control and VEGF + mIgG, respectively. D. U87 cells expressing non-sense RNA or Flk-1 shRNA GFP-vector were subjected to
tube formation in the presence of VEGF (10 ng/ml). Tubules were imaged with a phase contrast and fluorescent microscope. n=3. Data
were quantified. *P<0.05 compared with corresponding control cells bearing scrambled RNA.
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3.3.5 Inhibition of VEGF does not alter Flk-1 activated signaling
We then sought to determine if Flk-1 kinase activity plays a core role in signaling
activation independent of VEGF. Both U87 cells and GSDCs were treated with either SU1498 or
Bevacizumab overnight (Figure 3.7A). Consistent with earlier functional analyses, treatment of
these cells with SU1498 resulted in 80-86% reduction of tyrosine phosphorylated Flk-1
compared with control levels (Figure 3.7A+B). In contrast, Bevacizumab failed to alter pFlk-1
levels. To further identify intracellular signaling pathways in response to Flk-1 activation, we
focused on FAK and downstream effector MAP kinase Erk1/2, as these intracellular factors
mediate Flk-1 signaling in vascular endothelial cells (Yamashita J, et al. 2000, Shao, Hamel, et al.
2009). We measured tyrosine phosphorylated FAK and Erk1/2 after treatment of U87 cells and
GSDCs with Bevacizumab and SU1498, and we found that activated levels of pFAK in SU1498treated cells were reduced by approximately 50-75% relative to control or Bevacizumab-treated
cells (Figure 3.7A+B). Accordingly, pErk1/2 were significantly decreased in SU1498 but not
Bevacizumab-treated cells. As a result, SU1498 treatment led to suppression of SMa expression
by 67-75% compared with the level in control or Bevacizumab-treated cells. All the data
demonstrate that Flk-1 activation in tumor cells leads to intracellular signaling cascades FAK and
Erk1/2, and SMa expression; but this event does not require VEGF stimulation.
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Figure 3.7 Flk-1-mediated intracellular signaling activation is independent of VEGF.
A. U87 cells and GSDCs were treated with either Bevacizumab (Beva, 10 g/ml) or SU1498
(12.5 M) overnight and then collected for co-immunoprecipitation with an anti-pY20
antibody followed by immunoblotting with an anti-Flk-1 or FAK antibody. IgG of the anti-pY20
antibody was tested as loading controls. Some of these cell lysates were used for
immunoblotting against Flk-1, FAK, pErk1/2, Erk1/2, and actin. In addition, some cells were
treated with Beva 10 g/ml) or SU1498 (12.5 M) for three days, and then lysates were
measured for SMa expression. B. Active forms of pFlk-1, pFAK, pErk1/2, and SMa were
quantified by normalization with their corresponding total non-phosphorylated forms or actin.
n=3. *P<0.05 compared with corresponding control or Beva-treated groups.
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3.3.6 MAPK Participates in VM Signaling
In order to further confirm the intracellular signaling pathway mediating Flk-1
activation, we used a MAPK inhibitor, PD98059 (10 M). Protein expression levels of both
pErk1/2 and SMa were reduced by the inhibitor by 35% and 60% for U87 cells and 33% and 50%
for GSDCs relative to the DMSO control (Figure 3.8A+B). Like Flk-1 inhibition, PD98059 reduced
tube formation in both U87 and GSDC cells by 68% and 79% respectively (Figure 3.8C). All the
data support the notion that Erk1/2 participate in vascular signaling pathway.
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Figure 3.8 Inhibition of downstream ERK signaling yields similar results to Flk-1 inhibition.
A. U87 or GSDC cells were either untreated (CON) or treated with DMSO, or a MAPK inhibitor
(PD98059, 10 M) overnight and lysates were collected. Immunoblotting of the lysates for
Erk1/2, pErk1/2, SMa, and actin expression was performed. B. Quantification of amounts of
SMa and pErk1/2 shown in part A. C. Quantification of the functional analysis of the MAPK
inhibitor on tube formation of either U87 or GSDC cells on Matrigel. n=3, *P<0.05 compared
with corresponding control groups.
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3.3.7 GSDCs Form VM in Animal Models in vivo
In an attempt to determine if these GBM-derived tumor cell lines can develop VM in
vivo, we utilized a tumor xenograft model by transplantation of GSDCs into SCID/Beige mice. Six
of mice receiving GSDCs rapidly developed tumors in the eight-week period and removed
tumors were analyzed for tumor vasculogenesis. PAS staining revealed vigorous formation of
vasculature in the tumors (Figure 3.9A) reminiscent to its original vascular phenotype in GBM
(Figure 3.1B). These extensive vascular channels expressed strong SMa (Figure 3.9B), GFAP
(Figure 3.9C), and Flk-1 (Figure 3.9D), in which blood cells were located.

In addition, these

tumor cell-derived vessels did not express mouse CD31 (Figure 3.9E+F), confirming that VM is
divergent from endothelial cell angiogenesis. To test the possibility that GSDCs may undergo
differentiation in vivo into endothelial cells that participate in angiogenesis, we employed
different antibodies specific for recognizing human endothelial cells. Neither using an antihuman CD31 antibody nor an anti-CD34 antibody showed positive staining in the tissue (Figure
3.9G+H), which indicates incapability of tumor cell transdifferentiation into endothelial cells. To
validate that these Flk-1-positive vessels are derived from tumor cells, not from host endothelial
cells, we employed a co-immunofluorescent assay in which GFAP and Flk-1 were stained with
red and green fluorescence, respectively. Indeed, Flk-1-positive vascular channels co-expressed
GFAP that is specific for glioblastoma cells (Figure 3.9I+L). Finally, in order to demonstrate that
these GBM-lined VM channels were functional in vivo, we utilized primary GBM cells expressing
GFP, together with an intravenous injected fluorescent dye known as Evan’s blue 30 minutes
prior to sacrificing (Figure 3.10). Evan’s blue was detected in the lumen of GFP+ vessels,
highlighting that these vascular channels are functional in vivo. These in vivo data suggest that
transplanted glioblastoma cells participate in VM, rather than endothelial cell angiogenesis.
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Figure 3.9 GSDCs develop tumors that consist of tumor cell-associated vasculature coexpressing SMa, GFAP, and Flk-1.
Eight weeks following subcutaneous transplantation of GDSCs, tumors were removed and
processed for IHC analysis of PAS (A), co-staining of SMa and PAS (B), GFAP and PAS (C), Flk-1
(D), GFAP and mCD31 (E), SMa and mCD31 (F), hCD31 (G), hCD34 (H), and coimmunofluorescent staining of GFAP (I), Flk-1 (J) and DAPI (K) in which an overlay image was
displayed in (L). Black arrows (B, C, D, E, F) indicate positive staining of VM vessel markers.
Asterisks (C, D) specify the lumen of VM channels. White arrowheads (E, F) indicate positive
staining of endothelial cell vessel markers. White arrows (L) indicate VM channels. An insert
shows a large image for the channel. Bars: 100 m.
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Figure 3.10 Primary GBM cells form functionally active vessels in vivo.
Mice bearing primary GBM cell derived tumors (GFP positive) were intravenously injected with Evan’s Blue Dye 30 minutes
before sacrificing. Sections of the tumor tissue were analyzed for Evan’s blue atuofluorescence (red), GFP autofluorescence
(green). Representative pictures were taken of a tumor cell lined vessel, as Evan’s blue dye is clearly stained within that
vessel surrounded by a few GFP-positive tumor cells, indicating that this vessel is connected to the circulatory system. DAPI
(blue) was used to stain nuclei. A bar: 100 mm.
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3.3.8 Flk-1 is Vital to VM Development in vivo
In order to establish a functional role for Flk-1 in the development of VM and tumor
formation, we utilized another tumor xenograft model by transplantation of SCID/Beige mice
with U87 cells expressing either control vector or Flk-1 siRNA. All six animals receiving control
U87 cells developed palpable tumors within three weeks and all could be imaged for green
fluorescence by week 8 (Figure 3.11A+B). In contrast, tumorigenesis was significantly delayed in
mice receiving Flk-1 shRNA-expressing U87 cells, and they did not develop palpable tumors until
week 6. By weeks 6 and 8, these tumors were approximately 70% smaller than those observed
in control counterparts, and the fluorescent images were undetectable during this period
(Figure 3.11A+B). Post-mortem histological analyses of tumors revealed that the control tumors
harbored numerous tumor cell-derived channels, as demonstrated by extensive arbors of GFPpositive ramified channels throughout the entire tumor section (Figure 3.11C), the event that
resembled mural-like cell lined channels identified in GBMs and above GSDC tumors (Figure 3.1
+ Figure 3.9). In concert with earlier findings, the concomitant expression of PAS, SMa, and
CD31 distinguished tumor cell-lined vasculature from endothelial cell vessels. SMa-positive
vessels in control tumors were 7-fold greater than those found in shRNA tumors (Figure 3.11C-c,
C-d, and D). While SMa-positive channels were minimal in tumors expressing Flk-1 shRNA, a
significant fraction of vessels showed positive staining for mCD31, suggesting that endothelial
cells orchestrate blood vessels in the absence of VM (Figure 3.11C-e and C-f). In addition, IHC
analysis using a single anti-hCD31 antibody revealed no detectable signal in either condition of
tumors, consistent with early findings (Figure 3.9G+H). These results indicate lack of endothelial
cell transdifferentiation from tumor cells (Figure 3.11Cg and Ch). Collectively, all the in vivo data
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demonstrate that GBM cells promote VM, dependent on Flk-1; while host endothelial cells
contribute to tumor angiogenesis.
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Figure 3.11 Flk-1 shRNA in U87 cells inhibits tumor growth and VM.
A. Flk-1 gene knockdown results in suppression of tumor growth. U87 cells expressing Flk-1
shRNA-GFP or GFP vector were injected subcutaneously into SCID/Beige mice and tumor
size was measured weekly for 8 weeks. n=6. *P<0.05 compared with corresponding
controls. B. Tumor fluorescence was detectable only in mice injected with U87 cells
expressing GFP vector. Before sacrifice, mice were examined for tumor fluorescence.
Each image represented a single animal imaged 8 weeks after injection of the cells. C.
Formation of tumor cell-associated vascular channels was inhibited by Flk-1 gene
knockdown. Tumor fragments were examined for GFP fluorescence (a & b) and further
analyzed by IHC for expression of co-staining of SMa with PAS (c & d), SMa with mCD31 (e
& f), and a single staining of hCD31 (g & h). Arrows indicate GFP-positive (a) or SMapositive tumor-cell-lined channels (c & e). Bars: 50 m. D. Quantification of vessels of
VM and angiogenesis. Density of SMa and CD31-positive vessels present in (e & f) was
analyzed as described in the Methods. n=6. *P<0.05 compared with corresponding control
tumors.
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3.4 Discussion
Tumor vasculature is traditionally assumed to arise from an endothelial cell origin
(Folkman 1971). However, mounting evidence suggests that VM, the matrix-embedded, bloodperfused microvasculature, is an alternative mechanism for the development of tumor vessels,
independent of endothelial cell angiogenesis (Maniotis, et al. 1999, Folberg and Maniotis 2004).
For example, highly aggressive melanoma cells generate numerous matrix-rich patterned
channels containing blood cells, and the formation of these channels positively correlates with
the tumor malignancy (Hendrix, et al. 2003, Folberg, Arbieva, et al. 2006). A mosaic model
consisting both of tumor cell and endothelial cell-integrated networks was also described in the
development of colon cancer (di Tomaso, et al. 2005, Chang, et al. 2000). Other recent reports
suggest that mural-like tumor cells differentiated from GSCs promote VM (Soda, et al. 2011,
Wang, et al. 2010, Ricci-Vitiani, et al. 2010). Consistent with these data, we identified that blood
vessels of VM in GBM are comprised of mural cell-lined vasculature, while endothelial cells
contribute to angiogenesis, highlighting the different targets for clinical therapy. Furthermore,
we demonstrate that tumor cell lines developed from GBM possess mural cell properties
capable of forming vascular channels and this vasculogenesis is dependent on Flk-1 activity.
VM has recently received considerable attention in the study of tumor development in
clinic, because a simplistic vasculature model focusing on endothelial cell angiogenesis merely is
deemed insufficient to describe the entity of sophisticated neovascular networks in which tumor
cells also participate (Döme, et al. 2007, Folberg, Hendrix and Maniotis 2000).

For example,

clinical trials of recurrent GBMs with Bevacizumab alone for inhibition of VEGF-induced
angiogenesis did not result in significant improvement of disease survival (Bergers and Hanahan
2008, Verhoeff, et al. 2009, Kreisl, et al. 2009). Thus it is conceivable that the evasive responses
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may be at least in part attributed to VM. Indeed, our studies using Bevacizumab in vitro found
that this Flk-1-mediated vascularization is VEGF-independent.
Flk-1 emerges as an essential angiogenic mediator to trigger signaling cascades induced
by VEGF because of the expression of Flk-1 by endothelial cells. But this expression is not limited
to endothelial cells only; instead, a number of non-endothelial cells including stem cells and
some tumor cells also express Flk-1. For example, expression of Flk-1 acquired by embryonic
stem cells confers differentiation into cardiac tissue and vascular cells such as endothelial cells
and mural cells (Yamashita J, et al. 2000, Yang L 2008, Taura, et al. 2009). Flk-1+-neural stem
cells have the potential to give rise to vascular endothelial cells (Wurmser, et al. 2004). In this
study, we found that GBM-derived tumor cell lines express Flk-1 that controls VM in a VEGFindependent fashion. Furthermore, activation of Flk-1 triggers intracellular signaling cascades
from FAK to MAPK Erk1/2, resembling angiogenic signaling in endothelial cells (Yamashita J, et
al. 2000, Shao, Hamel, et al. 2009).

Although molecular mechanisms that regulate Flk-1

activation are currently still enigmatic in these cells, it is quite possible that it can be activated
indirectly by other factors present in tumor microenvironment such as extracellular matrix
proteins. Most of these proteins (e.g. fibronectin) can bind to membrane-associated integrins
and induce coordination of integrins with Flk-1, leading to Flk-1 activation (Eliceiri 2001,
Wijelath, et al. 2002, Borges, Jan and Ruoslahti 2000).

It is also possible that Flk-1 could be

mutated to lose its binding affinity with VEGF or become constitutively active in the cells.
Animal tumor models deficient of VEGF seem to be necessary to establish the notion that Flk-1
is an indispensable receptor tyrosine kinase independent of VEGF, which regulates mural cellassociated VM in GBM.
An anti-VEGF therapy with Bevacizumab was approved for the first-line treatment of a
variety of advanced carcinomas including brain tumor (Nghiemphu, et al. 2009), breast cancer
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(Miller, et al. 2007), colorectal cancer (Hurwitz, et al. 2004), and non-small-cell lung cancer
(Sandler, et al. 2006, Manegold 2008). However, the outcomes of this anti-angiogenic therapy
in advanced tumors are still controversy. For instance, a long term of the monotherapy with
Bevacizumab in GBMs only receives transitory benefit without significantly prolonged survival
(Norden, Drappatz and Wen 2009, Norden, Young, et al. 2008). Once the therapy stops, tumors
undergo vascular recovery and rapidly regrow.

Analogous to these clinical reports, evidence

from animal studies using either anti-VEGF or VEGF receptor therapy shows opposite results
including blood revascularization, increased invasiveness, and distant metastasis (Ebos, et al.
2009, Mancuso, et al. 2006, Keunen, et al. 2011). However, some interesting evidence from
both clinical and preclinical trials using Flk-1 kinase inhibitors AZD2171, SU5416, or an anti-Flk-1
antibody showed promising responses as these therapies ameliorate vascular normalization and
alleviate peritumoral edema in GBMs and other cancers as well (Batchelor, et al. 2011, Kamoun,
et al. 2009, Winkler, et al. 2004, Timke, et al. 2008, Kozin, et al. 2001). In line with these data,
our current findings have supported the hypothesis that VEGF and Flk-1 may independently
regulate diverse vascularizations through divergent vascular cells in GBM.

Therefore, the

conjunct therapies against both VEGF and Flk-1 could be taken into account for the treatment of
patients with GBM.
Our animal models derived from both U87 cells and GSDCs exhibited extensive vascular
channels formed by mural cells, recapitulating the vascular phenotype of GBM in which murallike cell-associated vascular channels constitute a major component of vasculature.
Interestingly, using an anti-human CD31 antibody failed to identify vessels positive for hCD31,
demonstrating that tumor cells, unlike GSCs, are unable to undergo differentiation into
endothelial cells. However, it is noteworthy that there is a significant population of mouse
CD31-positive endothelial cells that are associated with tumor angiogenesis. This host-derived
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angiogenic response is plausibly ascribed to the accumulation of angiogenic factors secreted
from the xenotransplanted tumor cells.

Nevertheless, the mural cell-associated, Flk-1-

dependent VM, but not endothelial cell angiogenesis, plays an essential role in the tumor
development.
It is also important to note that we used DMEM media supplemented with 10% FBS to
grow both the U87 cell line and the primary GBM cell line, GSDC. In a separate study by Lee et
al, they demonstrated the cancer cell lines grown in serum free media supplemented by growth
factors could cause cells to have a phenotye and genotype more indicative of primary tumors
(Lee, et al. 2006). Therefore, we cannot rule out a pheno/genotypic change in the U87s or
GSDCs in the presence of serum. Nonetheless, the vascular phenotype in vivo of our cell lines
resembles the observed vasculature in GBM patient tumors, indicating the VM mechanism
represents the human condition to a certain extent.
In sum, our current findings provide mechanistic insights into the development of VM by
tumor cells, the vascularization that occurs in a wide array of human cancers apart from GBM
such as melanoma (Maniotis, et al. 1999), breast cancer (Basu, et al. 2006), prostate cancer (Liu,
et al. 2002), colorectal cancer (Chang, et al. 2000), and ovarian cancer (Sood, et al. 2002).
Identification of Flk-1 as a key factor regulating VM could offer a novel therapeutic target for the
patient treatment. As a result, multiple anti-vascular approaches including targeting VM and
angiogenesis together with chemotherapy may represent the best possible regimen in the fight
against this devastating disease.
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3.5 Materials and Methods
3.5.1 Cell Culture
U87 cells were purchased from ATCC. GSDCs were established from a tumor sample of a patient
with GBM after the study was approved by Baystate Medical Center Institutional Review Board.
Briefly, a small fragment of a tumor sample was digested with an enzymatic mixture containing
1.3 mg/ml Trypsin (Sigma, St. Louis, MO), 0.67 mg/ml type 1-S hyaluronidase (Sigma), and 0.13
mg/ml kynurenic acid (Sigma). Following extensive wash, cells were re-suspended and cultured
in DMEM/F12 supplemented with B27 (Invitrogen, Carlsbad, CA) and 20 ng/ml bFGF and EGF for
2 weeks. Then the cells were transferred to a new plate and grew in DMEM supplemented with
10% FBS as the same medium used for U87 cells. GSDCs at passages between 10 and 20 were
used for the study. Human microvascular endothelial cells (HMVECs) established previously
were grown in a medium of EBM2 kit supplemented with hydrocortisone, EGF, and 10% FBS
(Lonza Inc, Allendale, NJ)(27).

3.5.2 Tube formation
Tube formation was performed as described previously (Francescone, Faibish and Shao 2011).
In brief, cells were plated on growth factor-reduced Matrigel (10 mg/ml, BD Lab, Bedford, MA)
overnight and tubules were fixed with 10% formalin and imaged followed by quantification.
Density of tubules was quantified from random selection of three fields under a microscope.

3.5.3 Flk-1 gene knockdown
A PGPU6-GFP-neo shRNA expression vector containing DNA oligos (21 bp) (GenePharma,
Shanghai, China) specifically targeting C-terminal (5’-GCTTGGCCCGGGATATTTATA-3’) of Flk-1 or
the vector with non-sense oligos as a control were transfected into U87 cells using Fugene 6.
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Cells were selected in 800 g/ml of G418 starting 48 hr after transfection and GFP expression
was monitored to evaluate transfection efficiency.

3.5.4 Immunoprecipitation and Immunoblotting
Cell lysates were processed as described previously (Shao, Hamel, et al. 2009). The lysates were
then incubated with an anti-pY20 antibody (ICN Biomedicals, Aurora, OH) at 40C overnight
followed by incubation with protein A sepharose beads at 40C for 4 hr. The immunocomplex
was extensively washed and the samples were run on SDS-PAGE. Then proteins were
transferred to a PVDF membrane (VWR, Rockford, IL) and incubated with an anti-Flk-1
monoclonal (Santa Cruz Inc., Santa Cruz, CA) or anti-FAK polyclonal antibody (Biosource,
Camarillo, CA). Membranes were then incubated with a goat anti-mouse secondary antibody
(Jackson Lab, Bar Harbor, Maine).

Specific signals were detected by enhanced

chemiluminescence (VWR). For immunoblotting only, blot membranes were incubated with one
of a series of primary antibodies against Flk-1, CD31, Tie1, Tie2 (Santa Cruz), SMa (Abcam,
Cambridge, MA), VE-, N-cad (Invitrogen, Piscataway, NJ), FAK (Biosource), pErk1/2, Erk1/2 (Santa
Cruz), or actin (Sigma).

3.5.5 Immunocytochemistry
Cells plated on 24-well plates were fixed with 4% paraformaldehyde and permeabilized with
0.5% Triton-X 100 in PBS. The samples were incubated overnight with antibodies specific for
Flk-1 (rabbit), VE-cad (mouse), and SMa (rabbit). Alexa Fluor 488 and 555 goat anti-mouse and
rabbit antibodies (Invitrogen) were added for 1 hr followed by nuclear staining with 4',6diamidino-2-phenylindole (DAPI) (Invitrogen).
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3.5.6 Live/Dead Assay
Live/Dead Assay Kit (Invitrogen) was employed to determine living vs. dead cells as instructed by
the manufacturer. Briefly, living cells were stained with 2 µM Calcein AM (green) and dead cells
were stained with 4 µM ethidium homodimer (red) for 30 minutes. Cells were then imaged and
live/dead cells were quantified.

3.5.7 Tumor xenografts in mice
All animal experiments were performed with the approval of Institutional Animal Care and Use
Committee of the University of Massachusetts and Baystate Medical Center. SCID/Beige mice
were injected subcutaneously with U87 cells (8 x 10P6) or GSDCs (5 x 106) in 0.2 ml of PBS.
Tumors arising from injected cells were monitored weekly for 8 weeks, after which the animals
were humanely sacrificed. Mice were examined for expression of GFP using the Maestro in vivo
imaging system (CRI, Woburn, MA). The tumors were measured and volume was calculated as
follows: volume = length x widthP2 x 0.52.

3.5.8 Immunohistochemistry and immunofluorescence
Paraffin-embedded or frozen tumor tissues were cut to 6 m thickness and processed for
immunohistochemical analysis. In brief, samples were incubated with 3% H2O2 for 30 min to
block endogenous peroxidase activity, followed by incubation with blocking buffer containing
10% goat serum for 1 hr. The samples then were incubated at room temperature for 2 hr with
mouse anti-Flk-1 (1:200) (Santa Cruz), anti-hCD31 (1: 100), anti-hCD34 (1:200), anti-SMa (1: 500)
(Dako Inc, Carpentaria, CA), rat anti-mCD31 (1: 50, BD Bioscience, San Jose, CA) monoclonal
antibodies, or rabbit anti-PDGFR, (Santa Cruz), anti-GFAP (1:5000, Dako) polyclonal antibodies.
Goat anti-mouse or anti-rabbit secondary antibodies (1: 100) conjugated to HRP were added for
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one hr. Finally, DAB substrate (Dako Inc) was introduced for several minutes and after washing,
methyl green or PAS was used for counterstaining. Dual immunohistochemistry labeling was
performed using one primary antibody at 4oC overnight followed by application of the
secondary antibody conjugated to alkaline phosphatase and incubated with permanent red as a
substrate (G2 Kit, Dako). After extensive washing with TBST, the samples were then incubated
with another primary antibody at room temperature for 2 hrs followed by application of a
secondary antibody conjugated to HRP.

Finally, DAB substrate and counterstaining were

performed as described above.
Vasculature quantification: Three to five specimens randomly cut from each tumor block were
processed for the IHC staining. Following the double staining with SMa and CD31, each sample
was subjected to quantification of all the vessels that were positively stained for SMa, CD31, or
both SMa and CD31, and that were negative staining but contained blood cells in the lumens.
NIH ImageJ software was used to quantify vessel density.
For dual immunofluorescent staining, tumor specimens were incubated with a mouse antihCD31 or Flk-1 for 2 hr followed by incubation with a goat anti-mouse Alexa Fluor secondary
antibody (1: 250) for 1 hr. Then the samples were similarly incubated with a rabbit anti-SMa or
GFAP antibody followed by incubation with a goat anti-rabbit Alexa Fluor antibody. Finally, DAPI
was added to stain nuclei.

3.5.9 Statistics
Data are expressed as mean ± SE and n refers to the numbers of individual experiments
performed.

Differences among groups were determined using one-way ANOVA analysis

followed by the Newman-Keuls test. The 0.05 level of probability was used as the criterion of
significance.

88

CHAPTER 4
TUMOR-DERIVED MURAL-LIKE CELLS COORDINATE WITH ENDOTHELIAL CELLS: ROLE OF YKL-40
IN MURAL CELL-MEDIATED ANGIOGENESIS
The work presented in this chapter was done in collaboration with, Nipaporn Ngernyuang, Wei
Yan, and Brooke Bentley. Parts of this chapter are taken from the published work: Francescone
R, Ngernyuang N, Yan W, Bentley B, Shao R. Tumor-derived mural-like cells coordinate with
endothelial cells: role of YKL-40 in mural cell-mediated angiogenesis. Oncogene. 2013. May 13.
Epub.

4.1 Introduction
Neo-vascular networks function to deliver nutrients, oxygen, and other molecules to
developmental tissue or pathologic lesion, the process known to mediate vasculogenesis and
angiogenesis (Hanahan 1997, Hanahan and Folkman 1996). The key step of this event involves
the formation of the neo-vasculature wall that is primarily composed of both endothelial cells
and mesenchyme-derived mural cells including smooth muscle cells and/or pericytes (Jain
2003). In physiological angiogenesis (e.g. wound healing), endothelial cells initially sprout to
form neo-vessels followed by recruitment of mural cells in a paracrine manner dependent on
PDGFB-PDGFRβ and angiopoietin-1-Tie-2 reciprocal activation (Hellström, et al. 2001, Bloch, et
al. 2000). It is acknowledged that vasculature in the central nervous system contains the highest
amount of mural cell coverage (Armulik, Genové and Betsholtz 2011).
Once mural cells are recruited onto the abluminal surface of endothelial cell-based
vessels, intercellular junctions between endothelial cells, mural cells, and/or endothelial-mural
cells act as a central factor to render the vascular network mature and stable. A number of
intercellular adhesion molecules are appreciated to regulate vessel fenestration, permeability,
and stability. For instance, vascular endothelial cadherin (VE-cadherin) plays an important role
in controlling endothelial-to-endothelial cell contacts (Carmeliet P 1999, Dejana, Orsenigo and
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Lampugnani 2008, Orlova, et al. 2006), while neural cadherin (N-cadherin) mediates endothelialto-mural cell and mural-to-mural cell communication (Paik, et al. 2004, Gerhardt, Wolburg and
Redies 2000, Luo, et al. 2006). A key intracellular mediator of the cadherin-associated cell-tocell contacts is β-catenin that acts as a physical link to the cytoskeleton assembly including actin
(Dejana, Tournier-Lasserve and Weinstein 2009, Vestweber 2008). Disruption of the complex
between cadherins and β-catenin results in decreased cell-cell interactions and increased cell
permeability.

Other gap junction proteins such as claudins, occludin, and connexins also

participate in distinct intercellular interactions (Jain 2003, Armulik, Genové and Betsholtz 2011).
The spatial cooperation and regulation of these cell-cell tight contacts commit endothelial cells
and mural cells to orchestrate the vessel wall, which offers adequate nutrients and oxygen for
tissue proliferation.
Although it remains to be clarified if different identities and/or functions of mural cells
exist between tumor and normal vessels, chaotic vasculature with either abundant or
insufficient coverage of mural cells is frequently observed during tumor angiogenesis (Carmeliet
and Jain 2011). Deletion of mural cells in tumor-bearing mice exhibited an impaired vascular
phenotype with diminished mature vessel formation and increased vessel permeability, thus
retarding tumor progression (Huang, et al. 2010, Abramsson, Lindblom and Betsholtz 2003). As
the most potent angiogenic factor, vascular endothelial growth factor (VEGF), also known as a
vascular permeability factor, promotes endothelial permeability and destabilizes vascular
integrity via interrupting VE-cadherin function in endothelial cells (Weis, et al. 2004, Gavard and
Gutkind 2006). In light of VEGF activity in mural cell coverage of tumor vessels, there is strong
evidence indicating that ablation of myeloid cell-derived VEGF in mice led to increased mural
cell coverage of the vessels and acceleration of tumorigenesis. These findings unveil a new
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pathologic signature of VEGF in functional inhibition of mural cell-associated vessels (Greenberg,
et al. 2008, Stockmann, et al. 2008).
YKL-40 (human cartilage glycoprotein-39 or chitinase-3-like-1) is a secreted glycoprotein
that was originally identified from culture medium of a human osteosarcoma cell line MG-63
(Johansen, Williamson, et al. 1992). Human YKL-40 protein contains an open reading frame of
383 amino acids with a molecular mass of 40 kDa and it is a member of glycoside hydrolase
family 18 that contains chitinases. But YKL-40 can only bind chitin-like oligosaccharides and
does not have chitinase/hydrolase activity because of the substitution of an essential glutamic
acid with leucine in the chitinase-3-like catalytic domain (Renkema, et al. 1998, Fusetti, et al.
2003). YKL-40 is normally expressed by different cell types such as vascular smooth muscle cells
(Shackelton, Mann and Millis 1995), macrophages (Rehli, Krause and Andreesen 1997),
neutrophils (Kzhyshkowska, Gratchev and Goerdt 2007), chondrocytes (Hu, et al. 1996), and
synoviocytes (Nyirkos and Golds 1990). To date, its biophysiological function in those cells
including mesenchyme-derived mural cells/vascular smooth muscle cells is incompletely
understood.
Multiple independent studies have shown that high serum levels of YKL-40 are
correlated with metastasis and poor survival in a broad spectrum of human carcinomas
including breast cancer (Jensen, Johansen and Price 2003), colorectal cancer (Cintin, Johansen,
et al., Serum YKL-40 and colorectal cancer 1999), ovarian cancer (Hogdall, et al. 2003), leukemia
(Bergmann, et al. 2005), lymphoma (Hottinger, et al. 2011), and glioblastoma (Pelloski, Mahajan,
et al. 2005), suggesting that serum levels of YKL-40 serve as a diagnostic and prognostic cancer
biomarker.

We have recently demonstrated that YKL-40 acts as an angiogenic factor to

stimulate vascular endothelial cell development in breast cancer and brain tumors (Shao, Hamel,
et al. 2009, R. Francescone, S. Scully, et al. 2011). YKL-40 is also known to be associated with
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tumor mesenchymal transition, displaying a poor prognosis (Phillips, et al. 2006). However, it is
largely unknown how YKL-40-induced neo-vessels are stabilized to be functional and what the
role of YKL-40 plays in tumor vasculogenesis characterized by communication between
endothelial cells and mural cells.

4.2 Experimental Strategy
Here, we sought to explore the molecular mechanisms through which YKL-40 controls vascular
permeability, stability, and angiogenesis mediated by mural cells in addition to vascular
endothelial cells. To achieve this purpose, we took advantage of our recently established tumor
cells named GSDC that are originally derived from human brain tumors and behave as vascular
mural-like cells (R. Francescone, S. Scully, et al. 2012). This model demonstrates 1) tumors with
vigorous vasculature when they are transplanted in animals; 2) a mesenchymal phenotype
strongly expressing YKL-40, smooth muscle actin alpha (SMa), PDGFRβ, and vimentin; and 3)
YKL-40 expressed by mural-like cells acts as a key factor regulating tumor vascularization. The
current study has informed a key role of YKL-40 in both mural cell and endothelial cell biology
during tumor angiogenesis.

4.3 Results
4.3.1 Tumor vascular coverage, stability, and angiogenesis are dependent on GSDCs expressing
YKL-40.
To interrogate if YKL-40, a mesenchymal marker expressed by mural-like cells, GSDCs,
acts as a central factor to establish vessel stability and integrity during tumor angiogenesis, we
began our study by employing a gene knockdown approach utilizing a retroviral infection of
shRNA against the YKL-40 gene in GSDCs. Two shRNA constructs sufficiently suppressed YKL-40
expression by over 90% compared to a shRNA scrambled control, as examined by western
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blotting (Figure 4.1A). Accordingly, YKL-40 gene knockdown led to decreased expression of
SMa, a mural cell marker, and cell motility (Figure 4.1A-C).
To investigate a potential role of YKL-40 in tumor vascular stability, permeability, and
angiogenesis in vivo, we engaged an orthotopic xenografted tumor model by injecting GSDCs
expressing scramble RNA or one of YKL-40 shRNAs (shRNA 1) into the brains of SCID/Beige mice
for a 5-month observation period. After the mice were sacrificed, we examined tumor sections
for angiogenesis by staining CD31, an endothelial cell marker. GSDC control tumors revealed a
strong vascularized phenotype as an intense CD31-positive vessel density was found throughout
the entire tumor region (Figure 4.2A-a).

In contrast, YKL-40 shRNA tumors displayed a

significant reduction of the vessel density by approximately 60% (Figure 4.2A-b +B). In addition,
most of the vessels in the control tumors contained a visible lumen, whereas vessels in the YKL40 shRNA tumors were collapsed and vessel diameters diminished to 30% relative to the control
ones (Figure 4.2A-a, b, + B). An analysis of mural cell coverage by co-staining CD31 and SMa
indicated that over 90% of endothelial cell-based vessels in the control tumors were covered
with mural cells, in comparison with less than 40% of vessels lined with mural cells in the YKL-40
shRNA tumors (Figure 4.2A-c, d, & C). To distinguish vessels covered by the tumor-derived
GSDCs from those by host-derived mural cells, we similarly injected GSDCs carrying green
fluorescent protein (GFP) into different mice. The majority of endothelial cell vessels (CD31)
were surrounded by GFP-positive GSDCs at the abluminal site where GFP and SMa were colocalized, while a few vessels were stained with CD31 only (Figure 4.3A-F), suggesting that
tumor-derived mural-like cells make a significant contribution to tumor vessel coverage.
Consistent with this finding, YKL-40 was expressed by SMa-positive mural cells in addition to
tumor cells (Figure 4.3H + I). Vessel permeability was measured by diffusion of fibrinogen from
the blood circulation. A limited amount of fibrinogen was identified to be diffused out of
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capillaries in the control tumors, contrary to that in the YKL-40 shRNA tumors which contained
more than 6-fold greater diffusion of fibrinogen, indicative of leakier vessels (Figure 4.2A-e, f, +
Fig. D). These in vivo data suggest that YKL-40 expressed by GSDCs mediates vascular mural cell
coverage, stability, and angiogenesis.
To characterize effects of YKL-40 on tumor development, the tumors were tested for the
proliferation marker Ki67. GSDC control tumors displayed positive staining of Ki67 by 3.3-fold
greater than did YKL-40 shRNA tumors (Figure 4.2E + F). Monitoring tumor cell growth in
cultured condition revealed a decrease of cell proliferation by 10% in YKL-40 shRNA cells relative
to counterparts (Figure 4.2G), suggestive of partial contribution of YKL-40 to the cell growth. In
concert with tumor growth and angiogenesis, mice receiving control cells showed a trend
towards decreased overall survival as compared with YKL-40 shRNA mice over this 5-month trial
Figure 4.2H). In sum, the in vivo animal models gave rise to evidence supporting our hypothesis
that YKL-40 derived from mural-like cells plays a vital role in maintaining vascular permeability,
stability, and angiogenesis in tumors through mural cell coverage; thus fueling tumor growth
and development.
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Figure 4.1 YKL-40 gene knockdown reduces SMa expression and the migratory capacity of GSDCs.
A. Western blot of the YKL-40 shRNA and the corresponding decrease in SMa expression. Actin is used as a loading control. B. Scratch wound
migration assay at time point 0 h (Top panels) and 24 h later (Bottom panels) of the control and shRNA GSDCs. C. Quantification of the
scratch wound migration assay portrayed in (B.). N=3, * P≤0.05 compared to control.
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Figure 4.2 YKL-40 expression in GSDC-transplanted tumors is associated with vascular
stability, mural cell coverage, angiogenesis, and tumor growth.
A. Representative immunofluorescent images of control and YKL-40 shRNA GSDC brain
tumor sections from SCID/Beige mice depicted single staining of CD31 (red) (a, b) and
double staining of CD31 (red) with either SMa (green) (c, d) or fibrinogen (green) (e, f).
DAPI (blue) was used to stain the nuclei. B. Quantification of CD31 vessel density and
vessel diameter from A (a, b) as described in the Methods. The latter was an average of
individual luminal diameters. C. Quantification of percent mural cell coverage of CD31
vessels from A (c, d). The data were derived from the ratio of SMa density to CD31
density. D. Quantification of the ratio of fibrinogen vs. CD31 for vessel leakiness from A
(e, f), in which the ratio of fibrinogen density to CD31 density in the control tumors
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Figure 4.3 GSDCs cover a large portion of tumor vessels.
Brain tumor sections of SCID/Beige mice injected with GSDCs containing GFP were analyzed for GFP (A. + D.), CD31 (B),
GFP + CD31 (C), SMa (E.), or GFP + SMa (F). In A-C, most of vessels were lined by GSDCs indicated by arrows and a few
vessels were devoid of GSDCs indicated by arrowheads. In D-F, co-expression of GFP and SMa surrounding vessel
structures was shown by arrows. Mural cell-associated vessels expressing SMa but not GFP were indicated by arrowheads.
Tumor tissue from GSDCs was stained for YKL-40 with IHC (H) and for SMa (green) and YKL-40 (yellow) with coimmunofluorescent assay (I). Bars: 100 mm.
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4.3.2 YKL-40 expression is associated with strong intercellular contacts and adhesion of GSDCs
To explore molecular mechanisms that possibly mediate intercellular contacts and
vascular coverage found earlier in vivo, we examined expression and interaction of Ncadherin/β-catenin/SMa in control and YKL-40 shRNA GSDCs. While N-cadherin remained
unchanged, expression of β-catenin and SMa was decreased when the YKL-40 gene was knocked
down (Figure 4.4A and Figure 4.3A). In control cells, VEGF production was barely detectable;
but was dramatically up-regulated in YKL-40 shRNA cells. To determine if the interaction of Ncadherin with β-catenin and its downstream effector SMa was diminished due to the decreased
levels of β-catenin and SMa by YKL-40 shRNA, we performed a co-immunoprecipitation assay
followed by immunoblotting. Both interactions of N-cadherin with β-catenin and β-catenin with
SMa in control cells were stronger than those in YKL-40 shRNA cells (Figure 4.4B). Accordingly,
immunocytochemical analysis confirmed about two-fold higher association of N-cadherin with
β-catenin in the control cells than that in the YKL-40 shRNA cells (Figure 4.4C). Likewise, the
similar association patterns of β-catenin with SMa were found in these cells by
immunocytochemistry (data not shown). However, the reduced association of N-cadherin and
β-catenin in the YKL-40 shRNA cells could not be rescued by VEGF neutralization. These results
suggest that YKL-40 expression by GSDCs is associated with the interaction of N-cadherin, βcatenin, and SMa, independent of VEGF activity.
In order to determine if these altered cell-cell contacts lead to changes in intercellular
adhesion activity, we measured cell aggregation. YKL-40 shRNA inhibited cell aggregation by
55% compared to a control level (Figure 4.4D). Neutralizing N-cadherin via an anti-N-cadherin
antibody in control GSDCs resembled the inhibition of YKL-40 shRNA, and combination of the Ncadherin blockade and YKL-40 shRNA slightly enhanced the inhibition on cell-cell adhesion,
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implying that N-cadherin may contribute a primary role to YKL-40-mediated cell to cell adhesion
(Figure 4.4D). Overall, these data underscore the importance of YKL-40 in the ability of GSDCs to
maintain cell to cell junctions through the N-cadherin/β-catenin/SMa pathway.
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Figure 4.4 YKL-40 expression is associated with interaction of N-cadherin/β-catenin/SMa
and cell-cell adhesion in GSDCs.
A. GSDC control and YKL-40 shRNA cell lysates were probed for N-cadherin (N-cad), β-catenin
(β-cate), YKL-40, SMa, VEGF, and actin expression through western blotting. VEGF mRNA levels
were also tested by RT-PCR with GAPDH as a loading control. B. (Left) Immunoprecipitation of
N-cad from control and YKL-40 shRNA cell lysates was tested for its association with β-cate by
western blotting against β-cate. (Right) Immunoprecipitation of β-cate from control and YKL40 shRNA cell lysates was tested for its association with SMa by western blotting against SMa.
IgG protein levels were used to ensure equal levels of antibody pull down. C. GSDC control
and YKL-40 shRNA cells were treated with or without a neutralizing anti-VEGF antibody (100
ng/ml) overnight. Immunocytochemistry of N-cad (green) and β-cate (red) to determine
overlapping staining (yellow) indicated by arrows. Cell nuclei were stained by DAPI (blue). A
bar: 10 m. Quantification of co-staining between N-cad and β-cate by normalization of
overlapping images to cell number. N=3, *P≤0.05 compared with control. D. Representative
pictures of the cell aggregation assay. Cells were subjected to serum-free media with either
IgG or an N-cad neutralizing antibody (Ab, 50 g/ml) for one hour. Cell aggregates of 10 or
more cells were counted for each condition and quantified below. A bar: 100 m. N=3, *
P≤0.05 compared with control.
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4.3.3 GSDC-conditioned medium containing YKL-40 mediates intercellular contacts and
adhesion of endothelial cells
To explore effects of YKL-40 expressed by GSDCs on intercellular junctions of vascular
endothelial cells via a paracrine manner, we used conditioned media from control or YKL-40
shRNA GSDCs in the culture of human microvascular endothelial cells (HMVECs) and measured
intercellular contacts of VE-cadherin and β-catenin. HMVECs expressed a stronger level of VEcadherin than N-cadherin, suggestive of a main role of VE-cadherin in cell to cell contacts (Figure
4.5A). The media from control and YKL-40 shRNA cells did not alter expression of VE-cadherin,
N-cadherin, or β-catenin Figure 4.5A + Figure 4.6A).

However, like GSDCs, co-

immunoprecipitation studies showed that media from YKL-40 shRNA cells inhibited the
interaction of VE-cadherin with β-catenin, and β-catenin with actin in HMVECs (Figure 4.5 +
Figure 4.6B). A minimal level of N-cadherin/β-catenin association was detected in HMVECs
treated with conditioned media from either control or YKL-40 shRNA cells (data not shown).
Because VEGF secretion was significantly elevated in the conditioned media from YKL-40 shRNA
cells (Figure 4.4A), the increased VEGF may contribute mainly to the reduced VE-cadherin/βcatenin interaction. To test this possibility, we used an anti-VEGF neutralizing antibody in the
co-immunoprecipitation assay of HMVECs. VEGF blockade restored the association of VEcadherin with β-catenin (Figure 4.5B).

Consistent with the co-immunoprecipitation data,

HMVECs treated with conditioned medium of YKL-40 shRNA cells displayed reduced colocalization of VE-cadherin and β-catenin to 13% relative to control cell medium, and treatment
with an anti-VEGF neutralizing antibody recovered the co-localization to approximately 63% of
the control levels (Figure 4.5C + D). In addition, the cell aggregation analysis unveiled the similar
inhibition of cell to cell adhesion (by 46-54%) by conditioned media from YKL-40 shRNA, control
cells treated with a VE-cadherin neutralizing antibody, or YKL-40 shRNA cells treated a VEcadherin antibody (Figure 4.5E). To confirm the key role played by YKL-40 in endothelial cell to
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cell interaction, we also treated conditioned medium of the control GSDCs expressing YKL-40
with a neutralizing YKL-40 antibody (mAY) (Faibish, et al. 2011). The conditioned medium
containing mAY abolished the interaction between VE-cadherin and β-catenin relative to the
control mIgG medium (Figure 4.5F). Accordingly, the control GSDC medium in the presence of
mAY suppressed HMVEC aggregation by 60% compared to the aggregation in the presence of
mIgG (Figure 4.5G).

While neither the neutralizing anti-VEGF antibody nor mAY altered

expression of VE-cadherin, N-cadherin and β-catenin in HMVECs (data not shown), treatment of
control GSDCs with mAY inhibited YKL-40 expression; in contrast, the anti-VEGF antibody in YKL40 shRNA GSDCs induced VEGF (Figure 4.6C), suggestive of distinct responses of mural cells to
individual inhibitors. Collectively, these data suggest that YKL-40 may induce the VE-cadherin/βcatenin/actin pathway and cell to cell adhesion in endothelial cells, and that YKL-40 blockade
inhibits these effects, which is largely dependent on VEGF.
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Figure 4.5 YKL-40 mediates the interaction of VE-cadherin/β-catenin/actin and cell-cell
adhesion in HMVECs.
A. Western blot analysis of VE-cad (VE-cad), N-cad, β-cate, and actin protein expression
from the lysates of HMVECs treated with either control or YKL-40 shRNA GSDC-conditioned
media for 24 hours. B. Immunoprecipitation of VE-cad from the HMVEC lysates treated for
24 hours with conditioned media from control, YKL-40 shRNA, or YKL-40 shRNA cells plus an
anti-VEGF Ab (100 ng/ml) followed by immunoblotting of β-cate. IgG levels were used as a
control. Immunoprecipitation of β-cate followed by immunoblotting against actin was
similarly performed in HMVEC lysates. *P<0.05 compared with control. n=3. C. Double
staining of VE-cad (red) with β-cate (green) in HMVECs treated with conditioned media from
control, YKL-40 shRNA, or YKL-40 shRNA cells plus an anti-VEGF Ab to determine the extent
of co-localization (yellow) indicated by arrows. Nuclei (blue) were stained by DAPI. A bar:
20 m. D. Quantification of the immunocytochemistry images in part C, normalized to cell
number. N=3, *P≤0.05 compared to control. +P≤0.05 compared to control and YKL-40
shRNA. E. HMVEC aggregation was measured and quantified in the presence of GSDC
control or YKL-40 shRNA media with an anti-VE-cad Ab (50 g/ml). N=3, *P≤0.05 compared
to control. F. HMVECs were treated with GSDC control medium in the presence of mAY or
mIgG (10 g/ml) overnight. Cell lystates were subjected to immunoprecipitation with an
anti-VE-cadherin antibody followed by immunoblotting against -cate. G. HMVECs treated
with GSDC control medium in the presence of mAY or mIgG (10 g/ml) were measured for
cell aggregation. N=3, *P≤0.05 compared to control.
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Figure 4.6 Data quantification and immunoblots.
A. Quantified data from immunoblotting of VE-cad, N-cad, and b-cate normalized with
actin. B. Quantified data from immunoprecipitation and immunoblotting of VE-cad, bcate, and actin normalized with IgG. N=2-4. *P<0.05 compared with controls. C.
Control GSDCs and YKL-40 shRNA GSDCs were treated with mAY and a VEGF antibody,
respectively, overnight. The conditioned media were used for immunoblotting against
YKL-40 and VEGF.
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4.3.4 YKL-40, in contrast to VEGF, stimulates interaction of VE-cadherin with β-catenin in
HMVECs
In order to investigate the roles that YKL-40 and VEGF play individually in the association
between VE-cadherin and β-catenin in HMVECs, we treated the cells with recombinant protein
of VEGF or YKL-40. Treatment of HMVECs with YKL-40 or VEGF did not alter protein expression
of VE-cadherin, N-cadherin, or β-catenin (data not shown). However, YKL-40 induced the
interaction between VE-cadherin and β-catenin; in contrast, VEGF inhibited their association
(Figure 4.7A). The immunocytochemical analysis validated this result that YKL-40 significantly
increased co-localization of VE-cadherin and β-catenin by 60% relative to the control, while
VEGF treatment decreased their co-localization by 43% (Figure 4.7B + C). In a trial using
different concentrations of these proteins, VEGF (10 ng/ml) and YKL-40 (200 ng/ml) at the
pathologic levels were found to have more effects on these adhesion molecule interactions than
other concentrations (data not shown). The results indicate that YKL-40, in contrast to VEGF,
induces the interaction of VE-cadherin and β-catenin in HMVECs, further supporting the earlier
findings using GSDC-conditioned media expressing YKL-40.
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Figure 4.7 YKL-40 enhances interaction of VE-cadherin and β-catenin, but VEGF attenuates
the interaction in HMVECs.
A. (Top) HMEVC lysates treated 24 hr with serum-free medium (SFM) with or without 10
ng/mL VEGF, or 200 ng/mL recombinant YKL-40 were immunoprecipated with an anti-VEcad Ab and probed for β-cate by western blotting. IgG was used as IP control. (Bottom)
Quantification of the western blots above, normalized to IgG levels. *P<0.05 compared
with SFM. n=3. B. Representative images of VE-cad (red) and β-cate (green) double stained
HMVECs in the presence of either SFM, 10 ng/mL VEGF, or 200 ng/mL for 24 hr. White
arrowheads highlight the areas positively co-stained for VE-cad and β-cate (yellow). C.
Quantification of the VE-cad/β-cate overlap in the images in part C. A bar: 20 m. N=3,
*P≤0.05 compared to control.
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4.3.5 YKL-40 expressed by GSDCs mediates the cadherin/catenin complexes in co-culture of
GSDCs and HMVECs
To monitor the interaction of cadherin and catenin between endothelial cells and mural
cells that may recapitulate their functional relationship in vessels in vivo, we undertook an
immunocytochemical approach probing the co-localization of either VE-cadherin/β-catenin or Ncadherin/β-catenin in a cell co-culture system with GSDCs and HMVECs. Intense co-staining of
VE-cadherin/β-catenin was found in HMVECs mixed with control GSDCs, but this co-localization
was decreased by 58% in HMVECs when co-cultured with YKL-40 shRNA GSDCs (Figure 4.8A), in
which HMVECs were distinguished from GSDCs by positive staining of VE-cadherin as indicated
with white asterisks (Figure 4.8A). This is indicative that YKL-40 expressing cells are crucial to VEcadherin/β-catenin interaction in HMVECs.
Next, to determine the interaction between the N-cadherin and β-catenin in this coculture system, we labeled GSDCs only with nuclear staining DAPI prior to mixing with HMVECs,
because both cell types express N-cadherin and β-catenin. By this approach, we could discern
GSDCs (DAPI-positive) from HMVECs (DAPI-negative), and analyzed individual GSDC-GSDC,
HMVEC-HMVEC, and GSDC-HMVEC contacts (Figure 4.8B, top & bottom left). Membrane colocalization of N-cadherin and β-catenin between control GSDCs was found around 38% of GSDC
population, but this co-staining between YKL-40 shRNA GSDCs was reduced to 23% (around 40%
reduction compared with the control) (Figure 4.8B, bottom right). However, there was no
appreciable difference of their co-localizations in other cell types. In line with the findings
earlier using the single cell type system, the data suggest that YKL-40 mediates VE-cadherin/βcatenin

association

in

HMVECs

and

N-cadherin/β-catenin
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complex

in

GSDCs.
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Figure 4.8 Co-culture of HMVECs and YKL-40-expressing GSDCs displays interaction between cadherin and catenin.
A. (Top) HMVECs cultured with control or YKL-40 shRNA GSDCs were stained for VE-cad (red) and β-cate (green). White arrowheads
mark regions of co-localization of VE-cad and β-cate. (Middle) VE-cad (red) staining was to show HMVECs distinct from VE-cad-negative
GSDCs. White asterisks indicate HMVECs. DAPI (blue) was used as a nuclear stain for all images. (Bottom) Quantification of the
percentage of HMVECs that have co-expression (yellow) of both VE-cad and β-cate in a total of HMVECs. Bars: 10 m. N=3, *P≤0.05
compared to control. B. (Top) HMVECs and either control or YKL-40 shRNA GSDCs were cultured together and tested for overlapping of
N-cad (green) and β-cate (red). DAPI was pre-stained for the nuclei of GSDCs only, but not for HMVECs to discriminate different cell
types. (Bottom, Left) Representative images of the different types of cell to cell contacts: GSDC-GSDC (white arrowhead), HMVECHMVEC (black arrowhead), and HMVEC-GSDC (white arrow). (Bottom, right) Quantification of the percentage of cells containing Ncad/β-cate overlapping contacts in a total of individual cell types, displayed by cell contact types. Bars: 10 m. N=3, *P≤0.05
compared to control.
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4.3.6 YKL-40 expression by GSDCs is associated with restricted permeability of HMVECs and
GSDCs
To further evaluate permeability of HMVECs and GSDCs, one of the key vascular
functions, we utilized a permeability method that assays the ability of cells to be permeable to
Dextran conjugated with FITC. First, we treated HMVECs with either conditioned media from
control or YKL-40 shRNA GSDCs, and we found that control medium-treated HMVECs restricted
the permeability that allowed FITC-Dextran to cross through the cells 30% less than did YKL-40
shRNA medium-treated cells (Figure 4.9A, top graph). In order to verify the functional role of
VE-cadherin in HMVEC permeability, we added a VE-cadherin neutralizing antibody to the
media. While mIgG, as a control, did not have an impact in the permeability treated with
control or YKL-40 shRNA media, a VE-cadherin antibody increased cell permeability in control
medium-treated HMVECs (Figure 4.9A, middle graph). However, this VE-cadherin neutralization
in YKL-40 shRNA medium-treated cells failed to enhance the permeability induced by YKL-40
shRNA, consistent with HMVEC-HMVEC adhesion found earlier (Figure 4.5E). This implies that
VE-cadherin plays a key role in the elevated permeability of HMVECs treated with YKL-40 shRNA
media. In order to determine the effect of VEGF on permeability, as VEGF mediated the
disassociation of β-catenin from VE-cadherin (Figure 4.5B-D), we treated the HMVECs with an
anti-VEGF neutralizing antibody. The anti-VEGF antibody fully reversed the GSDC YKL-40 shRNA
medium-induced permeability to the level treated with GSDC control media (Figure 4.9A,
bottom graph). As expected, the anti-VEGF antibody did not have effects on the permeability of
control medium-treated HMVECs because of the considerably lower level of VEGF in the control
media. To validate this endothelial cell permeability restrained by YKL-40, we treated HMVECs
with mAY in the presence of GSDC control medium and found that mAY induced HMVEC
permeability by 51% (Figure 4.10A). These results suggest that YKL-40 maintains HMVEC
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permeability and that YKL-40 blockade destabilizes the permeability probably through VEcadherin activation.
Next, we assessed impacts of YKL-40 on GSDC permeability. GSDCs expressing YKL-40
shRNA exhibited a much higher permeability than control GSDCs, as the permeability of YKL-40
shRNA GSDCs was increased by up to 58% at 4 hr (Figure 4.9, top graph). Inhibition of Ncadherin using an anti-N-cadherin neutralizing antibody resulted in a 25% and 20% elevation in
the permeability of control and YKL-40 shRNA GSDCs, respectively, compared with mIgG
treatment over the 4-hr observation (Figure 4.9B, middle graph). Unlike an anti-VE-cadherin
antibody in HMVECs (Figure 4.9A, middle panel), blocking N-cadherin in YKL-40 shRNA GSDCs
enhanced cell permeability (by 20% compared with YKL-40 shRNA), analogous with the adhesion
result (Figure 4.4D), suggesting that other cell adhesion factors, in addition to N-cadherin, may
also participate in YKL-40-mediated cell adhesion and permeability. For example, inhibition of
integrins αVβ3 or αVβ5 partially increased cell leakage relative to N-cadherin inhibition (Figure
4.10B). To further validate that VEGF contributes to HMVEC, but not GSDC, permeability, we
treated GSDCs with an anti-VEGF antibody. As expected, this anti-VEGF antibody failed to have
an effect on the permeability of control or YKL-40 shRNA GSDCs that express strong VEGF
(Figure 4.9B, bottom graph). These results suggest that YKL-40 stabilizes GSDC permeability in a
manner mainly dependent on N-cadherin.
Finally, to evaluate the overall cell permeability mediated by both GSDCs and HMVECs
that would be more representative of vessel function in vivo, we loaded either control or shRNA
GSDCs first for 2 hours followed by plating HMVECs on the top of the GSDCs, which simulated
the vascular orientation from an “endothelial cell to mural cell” layer and encountered
penetration of FITC-Dextran. Co-cultured YKL-40 shRNA GSDCs with HMVECs induced the
“vascular” permeability by 25% greater than that of the system containing HMVECs and control
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GSDCs (Figure 4.10C). To assess the role of VEGF in cell permeability, we treated both cells with
an anti-VEGF antibody. Consistent with the results found in the single HMVEC system above,
VEGF abrogation suppressed the permeability of HMVECs induced by YKL-40 shRNA GSDCs to
the control level (Figure 4.9C). Dual treatment with VE-cadherin and N-cadherin antibodies in
HMVECs with either control GSDCs or YKL-40 shRNA GSDCs led to stronger increases in the
permeability than that induced by YKL-40 shRNA GSDCs in the presence of mIgG (Figure 4.9D),
suggesting that combined activities of VE- and N-cadherin contribute predominantly to the
vessel permeability. Collectively, all the data support the notion that YKL-40 controls vascular
permeability by regulating VE-cadherin and N-cadherin function in endothelial cells and mural
cells, respectively.
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Figure 4.9 YKL-40 decreases permeability of HMVECs, GSDCs, and their combination in a manner dependent on VE-cad
or N-cad activity.
A. HMVECs were plated on inserts and allowed to attach and spread. Cells were treated overnight with either GSDC
control conditioned media (CM, 24 hr serum-free media) or YKL-40 shRNA CM (Top), control or YKL-40 shRNA CM with
mouse IgG or an anti-VE-cad Ab (20 g/ml) (Middle), or anti-VEGF Ab (100 ng/ml) (Bottom). Cell permeability was then
measured using FITC-Dextran as described in the Methods. B. GSDC control or YKL-40 shRNA cells were used for the
same permeability assay (Top) as described in (A), in the presence of an anti-N-cad Ab (50 g/ml) (Middle) or VEGF Ab
(100 ng/ml) (Bottom). C. GSDC control or YKL-40 shRNA cells were first plated on the insert. 2 hr following attaching and
spreading, HMVECs were plated on the top of the GSDCs to form a second layer and allowed to attach and spread in the
presence of mIgG or an anti-VEGF Ab (100 ng/ml). The same permeability assay was performed on the next day. D.
GSDCs were pre-treated with mIgG or an anti-N-cad Ab (50 g/ml) overnight to exclude the possibility that the top layer
of HMVECs prevents the antibody from access to the bottom layer of GSDCs. Then, GSDCs and HMVECs were set up as
described in C in the presence of mIgG or an anti-VE-cad Ab (20 g/ml). The permeability was measured. N=6, *P≤0.05
compared to corresponding controls at the same time points.
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Figure 4.10 Effects of mAY, YKL-40 shRNA, and integrin antibodies on cell permeability.
A. HMVECs were plated in inserts and treated with conditioned medium (CM) of control GSDCs in the presence of mIgG or mAY (10 mg/ml)
overnight. Cell permeability was measured. B. Control GSDCs were plated in inserts in the presence of anti-N-cadherin (50 mg/ml), integrin
avb3, or avb5 antibody (10 mg/ml). Then, cell permeability was determined. C. GSDC control or YKL-40 shRNA cells were plated for 2 hr
followed by loading HMVECs on the top of the GSDCs. Cell permeability was determined on the next day. N=6, *P<0.05 compared with
corresponding controls.
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4.3.7 HMVEC-formed tubules are stabilized by GSDCs expressing YKL-40
In an attempt to assess if GSDCs indeed act as mural cells to stabilize endothelial cell
vessels, we employed a tube formation assay on Matrigel by co-culturing both HMVECs and
GSDCs. HMVECs pre-labeled with Calcein AM (green fluorescence) were mixed with either
control or YKL-40 shRNA GSDCs pre-labeled with Calcein red (red fluorescence). Stability of
tubules formed by HMVECs and GSDCs was monitored over a 64-hr time course. As shown in
Figure 4.11A, HMVECs co-cultured with control GSDCs maintained tubules longer than did
HMVECs in the presence of YKL-40 shRNA GSDCs. The breakdowns and gaps in the tube
network, indicated by arrows, were significantly less in HMVECs with control GSDCs at 24 hours
and 40 hours than corresponding HMVECs co-cultured with YKL-40 shRNA GSDCs (Figure 4.11A +
B). HMVECs alone maintained their own tubules only between 24-36 hr (data not shown). To
further validate the individual role of VE-cadherin and N-cadherin in vascular stability, we
treated this co-culture system with a VE-cadherin or N-cadherin neutralizing antibody. When
HMVECs co-cultured with control GSDCs were treated with either cadherin antibody, tubule
stability was decreased to the level seen in the co-culture of HMVECs and YKL-40 shRNA GSDCs
(Figure 4.11C + Figure 4.12). As expected in the system of HMVECs and YKL-40 shRNA GSDCs,
anti-VE-cadherin and N-cadherin antibodies were unable to influence the stability because of
impaired activity of VE-cadherin and N-cadherin by YKL-40 gene knockdown. To determine a
role of VEGF in the co-culture system, we treated HMVECs and control GSDCs with recombinant
VEGF, and we found that the addition of VEGF to the YKL-40-expressing system developed more
stabilized tubules than did control counterparts Figure 4.11C + Figure 4.12). The phenotype of
elevated tubes is probably due to the synergistic cooperation of these two strong angiogenic
factors for the tube generation and stabilization, as the vessel-destabilized property of VEGF
may be notably minimized in the presence of YKL-40. An anti-VEGF antibody partially rescued
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the tube stability formed by HMVECs and YKL-40 shRNA cells that express a high level of VEGF.
Failure of full tubule recovery in the presence of the anti-VEGF antibody is attributed to
impaired N-cad function, even when VEGF is inhibited. Thus, these data suggest that the ability
of GSDCs to stabilize endothelial cell-based vasculature is reliant on YKL-40 expression that
regulates VEGF, VE- and N-cadherin activity. Altogether, in coordination with tumor vasculature
found in vivo, the in vitro system identifying cell-cell contacts/adhesion, permeability, and
stability of vascular wall cells have provided the critical mechanisms strengthening our
conclusion that YKL-40 plays a central role in mural cell-mediated tumor angiogenesis via
autocrine and paracrine loops.
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Figure 4.11 GSDCs expressing YKL-40 stabilize endothelial cell vessels in a manner dependent on VE-cadherin and N-cadherin activity.
A. HMVECs and either control or YKL-40 shRNA GSDCs were pre-stained with Calcein AM (green) and Calcein red, respectively, and plated
together on Matrigel. Tube formation was analyzed over a 64-hour time course and representative images were shown at 16, 24, 40, and
64 hr. White arrows demonstrated breaks in the tube networks, while black arrows on the phase contrast images depicted gaps in the
corresponding networks. Bars: 100 m. B. Quantification of the tubules formed by HMVECs plus control or YKL-40 shRNA GSDCs. N=3,
*P≤0.05 compared to controls. C. Same condition as described in A was set up in the presence of recombinant VEGF (10 ng/ml), an antiVEGF (100 ng/ml), VE-cadherin (20 g/ml), or N-cadherin antibody (50 g/ml). 24 hr following incubation, tubules with fluorescence were
analyzed and quantified. N=3, *P≤0.05 compared to mIgG.
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Figure 4.12 Inhibition of VE-cadherin or N-cadherin activity leads to decreases in vascular stability.
HMVECs and either control or YKL-40 shRNA GSDCs were pre-labeled with Calcein AM (green) and Calcein red,
respectively, and plated together on Matrigel in the presence of an anti-VE-cadherin (20 mg/ml), anti-N-cadherin (50
mg/ml), or anti-VEGF antibody (100 ng/ml). 24 hr following incubation, tubule images with fluorescence were
analyzed. White arrows demonstrated breaks in the tube networks, while black arrows on the phase contrast images
depicted gaps in the corresponding networks. Note recombinant VEGF (10 ng/ml) in control and an anti-VEGF Ab in
shRNA. Bars: 100 mm.
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4.4 Discussion
We previously demonstrated that YKL-40 can induce endothelial cell angiogenesis in
tumors (Shao, Hamel, et al. 2009). Here, we have provided substantial evidence using brain
tumor-derived mural-like cells to uncover a new angiogenic role of YKL-40 in tumor vascular
permeability, stability, and activity characterized by the intimate interaction between
endothelial cells and mural cells. This finding was also supported by the identical mural-like
characteristics of brain tumor cells from different patients (data not shown). The reason for
selecting such mesenchyme-derived mural cells is because a considerable subset of brain
tumors (e.g. glioblastomas) express strong YKL-40 and demonstrate poorer prognosis with a
mesenchymal phenotype and vigorous vascularization (R. Francescone, S. Scully, et al. 2011,
Phillips, et al. 2006). In addition, the vasculature of the central nervous system is typically
covered with abundant mural cells in angiogenesis (Armulik, Genové and Betsholtz 2011). Thus,
the current study has advanced our knowledge about YKL-40 in both mesenchymal mural cell
and vascular endothelial cell biology during tumor vascularization. Furthermore, understanding
the regulation of the intercellular junctions that mediate the interaction between endothelial
cells and mural cells, rather than focusing on endothelial cells alone, has offered additional
mechanistic insights into the entity of the angiogenic process induced by YKL-40 in tumor
microenvironment.
In physiological angiogenesis, bone marrow-derived progenitor cells or myofibroblastic
precursors are appreciated as the primary mesenchymal origin capable of differentiating into
mural cells that involve vessel maturation (Chambers, et al. 2003, Tomasek, et al. 2002, Elenbaas
and Weinberg 2001). However, in tumor angiogenesis, transplanted tumor cells expressing
mesenchymal markers YKL-40, SMa, and vimentin were found to serve as a major component of
mesenchymal mural cells. This is the first time in our knowledge to provide evidence indicating
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that tumor-derived mural-like cells may functionally substitute host-derived mesenchymal mural
cells that are presumably deregulated in the scenario of highly vascular proliferation. Therefore,
the evidence enhances our understanding of potential functional and genetic differences in
different mural cell identities such as mesenchymal tumor-derived mural cells vs. host
mesenchyme-differentiated mural cells. YKL-40 supports vessel stability and maintains vascular
integrity mainly through activation of the N-cadherin/-catenin/SMa and VE-cadherin/catenin/Actin pathway in mural-to-mural cell and endothelial-to-endothelial cell contacts,
respectively. YKL-40 gene knockdown impaired these junctions, leading to vessel collapse and
leakage, as a schematic model is illustrated in Figure 4.13. To further support this model, an
additional study in vivo assaying vessel perfusion and oxygenation by injection of a hypoxia
probe will be essential. By this approach, dysfunction of tumor perfusion and oxygenation
ascribed to YKL-40 gene knockdown can be visualized. Thus, the characterization of tumor
vascular development in vivo, in context with the present findings from vascular permeability
and stability models using the co-culture systems, demonstrates that elevated YKL-40 mediates
vascular mural cell coverage, stability, and angiogenesis; ultimately fostering tumor cell
proliferation. These findings underscore a key role of YKL-40 in the establishment of tumor
angiogenesis mediated by the coordination of mural cells with endothelial cells.

Indeed,

focusing on mural cell-mediated vessel coverage and stabilization has recently received
significant attention in tumor neo-vascularization, the event that renders tumor cells evasive
during the conventional anti-angiogenic therapy. For example, melanoma deficient of mural
cells exhibited a leakier vascular phenotype and were more sensitive to an anti-VEGF drug
Bevacizumab than the tumors that harbored mural cell-covered vessels (Helfrich, et al. 2010),
highlighting a protective role of mural cells in exposure to an anti-angiogenic drug. Whether or
not YKL-40-stabilized vessels play the identical role in the drug resistance remains to be clarified,
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as it may hold therapeutic promise in patients who do not respond to angiogenesis-blocking
agents.
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Figure 4.13 A hypothetical model of vessel stability and angiogenesis mediated by YKL-40expressing mural cells.
A tumor blood vessel is covered with mural cells that express high YKL-40 levels. YKL-40
promotes cell-cell contacts of mural cells via enhanced N-cadherin/β-catenin interaction and
downstream effector SMa in an autocrine manner. In addition, YKL-40 also induces VEcadherin/β-catenin/actin association in endothelial cells in a paracrine loop. Once expression
of YKL-40 is inhibited, both mural cell and endothelial cell contacts are disrupted, which
impairs vascular permeability and stability. As a result, the diminished angiogenesis restricts
nutrients and oxygen delivery to the tumors, impeding the tumor growth.
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VEGF, a strong permeability factor, stimulates angiogenesis and tumor growth through
enhancing endothelial cell migration, proliferation, survival as well as vessel permeability or
destabilization of endothelial-to-endothelial cell contacts (Chen, et al. 2012, Ferrara and Kerbel
2005).

VEGF-induced

vessel

permeability

is

associated

with

VE-cadherin

tyrosine

phosphorylation and degradation. VEGF binds its membrane tyrosine kinase receptor 2 (Flk-1)
and induces Flk-1 tyrosine phosphorylation and activity that can activate VE-cadherin by Srcdependent tyrosine phosphorylation (Lambeng, et al. 2005, Nakamura, et al. 2008, Lin, et al.
2007). Subsequently, the activated VE-cadherin disassociates from Flk-1 and -catenin, and is
internalized to the cytoplasm where it is degraded. Thus, VE-cadherin phosphorylation leads to
the loss of cell-cell junctions and the increase in cell permeability (Shrivastava-Ranjan, Rollin and
Spiropoulou 2010, Gorbunova, Gavrilovskaya and Mackow 2010, Shay-Salit, et al. 2002). Our
current studies have provided multiple relevant results supporting this mechanism. For
example, stimulation of endothelial cells with VEGF reduced the association between VEcadherin and -catenin, and treatment with an anti-VEGF antibody in YKL-40 shRNA cells overexpressing VEGF facilitated the interaction of VE-cadherin with -catenin. VE-cadherin blockade
led to increased endothelial cell permeability, the effect identical to treatment of these cells
with YKL-40 shRNA medium expressing high levels of VEGF. In addition, this VE-cadherin
neutralization failed to enhance endothelial cell permeability induced by YKL-40 shRNA medium,
suggesting that functional loss of VE-cadherin mediates VEGF-induced cell permeability. It is
emerging that VEGF exhibits distinct impacts on endothelial cells and mural cells. Although we
did not find effects of VEGF on GSDC permeability, there is evidence demonstrating inhibitory
effects of VEGF on mural cell coverage of the vessels, thereby suppressing tumor development
(Greenberg, et al. 2008, Stockmann, et al. 2008). We also interestingly found that expression of
-catenin and SMa, in contrast to VEGF, was down-regulated in YKL-40 shRNA cells, suggesting
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that YKL-40 differentially regulates their expressions. Intracellular pathways mediating SMa and
VEGF expression involve PI3K and/or MAPK signaling, as a PI3K inhibitor Wortmannin or MAPK
inhibitor PD98059 blocked their expression in GSDCs (Figure 4.14). This finding is consistent
with our previous reports that PI3K-Akt and MAPK Erk-1 and Erk-2 mediate YKL-40 signaling in
the regulation of angiogenesis and cell survival in U87 cells and GSDCs (R. Francescone, S. Scully,
et al. 2011, R. Francescone, S. Scully, et al. 2012, Faibish, et al. 2011). It will also be interesting to
interrogate if a membrane receptor specific for YKL-40 mediates the activation and expression
of these molecules, as it is likely that the YKL-40 receptor interacts and coordinates with its
adjacent cadherins to induce intracellular signaling pathways.
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Figure 4.14 PI3K and MAPK signaling pathways mediate expression of SMa and VEGF
in GSDCs.
GSDCs were treated with PI3K inhibitor Wortmannin (10 nM) and MAPK inhibitor
PD98059 (10 mM) overnight. Cell lysates and media were collected to test N-cad, bcatenin, SMa, and VEGF in immunoblotting. Actin was a control.
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We utilized GSDCs derived from a glioblastoma patient and found this population
participates in the vascular stability and permeability, functioning as mural cells. YKL-40 shRNA
led to induction of VEGF, which seems to conflict with our previous findings in which YKL-40 upregulates VEGF in glioblastoma cells U87, a commercially available tumor cell line (R.
Francescone, S. Scully, et al. 2011). A number of possibilities might account for this discrepancy
observed in the different studies. First, the heterogeneity of tumor could contribute to the
difference of VEGF expression and its regulation by YKL-40, as glioblastomas contain several cell
subpopulations such as astrocytes, neurons, and oligodendrocytes, in addition to other vascular
cells and immune cells. Expression of VEGF is higher in U87 cells than that in GSDCs and another
glioblastoma cell line SNB-75 (data not shown). Indeed, YKL-40 and VEGF expression vary in
individual glioblastoma patients (R. Francescone, S. Scully, et al. 2011). Second, the elevation of
VEGF in GSDCs expressing YKL-40 shRNA may represent a compensating effect in angiogenic
responses during a chronic course of YKL-40 blockade, the event resembling the neutralization
of VEGF in U87 cells that also increased YKL-40 expression (R. Francescone, S. Scully, et al. 2011).
Neutralizing VEGF in YKL-40 shRNA GSDCs led to induction of VEGF expression, although the
neutralized VEGF is not functional, supporting the compensating responses of the cells to their
severely impaired angiogenic activities. Thus, those two vascular promoting factors coordinate
and regulate each other to render tumors vascularized. Supporting this speculation, VEGF
induced by YKL-40 in U87 cells stimulated endothelial cell tube formation, while in this study we
primarily focused on VEGF in endothelial cell permeability, these different events cooperative
for angiogenesis. In addition, adding VEGF to the co-culture system of YKL-40-expressing control
GSDCs and HMVECs induced and stabilized vascular tubes (Figure 4.11C).

It is currently

unknown which factor expressed differentially by U87 and GSDCs plays a key role in the
regulation of VEGF that divergently induces angiogenesis through the different cells. HIF-1is
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not a core factor to contribute to the differential expression of VEGF in both cells (data not
shown). Finally, even though it is currently unknown if U87 cells also mediate vascular stability
via VEGF expression controlled by YKL-40, it is conceivable that multiple molecular mechanisms
are involved in YKL-40-induced vascular stability and integrity, not limited to VEGF only. In the
present study, we found that vascular stability contributed by GSDCs is dependent on Ncadherin, in contrast to endothelial cell-mediated permeability that depends on activation of
VEGF-VE-cad.

Therefore, the regulation between YKL-40 and VEGF in tumor vascularization

relies on the function of individual cell populations that orchestrate tumor mass, vascular
endothelium, and/or mural cell (vessel supporting) network.

Recent pre-clinical and clinical trials have established a therapeutic paradigm
complementary to the conventional vessel-blocking regimen, in which normalization of tumor
vascular abnormalities impedes tumor development (Carmeliet and Jain 2011). Depletion of
mural cells in animal tumor models led to diminished blood vessels, increased tumor hypoxia,
and restrained tumor growth (Huang, et al. 2010). PDGF over-expression in patients was found
to be associated with metastasis (Liu, et al. 2011) and PDGF blockade that impairs mural cell
recruitment was reported to improve drug delivery and chemotherapy (Jayson, et al. 2005,
Hellberg, Ostman and Heldin 2010). It is also noteworthy that delivery of drugs targeting both
endothelial cells (e.g. VEGFR inhibitor) and mural cells (e.g. PDGFR inhibitor) was more
effective than individual anti-angiogenic drugs, because destabilizing vessels by inhibition of
mural cell function rendered endothelial cells more susceptible to endothelial cell blockers
(Erber, et al. 2004, Bergers, Song, et al. 2003). Despite these promising data, conflicting
evidence was also documented from several animal settings and clinical trials. For instance,
deletion of mural cells promotes metastasis probably due to lack of a barrier preventing tumor
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cells from dissemination into the circulation system (Gerhardt and Semb, Pericytes: gatekeepers
in tumour cell metastasis? 2008). Analogous with these findings, decreased mural cell coverage
around vessels in patients is correlated with cancer metastasis (Yonenaga, et al. 2005).
Although the molecular mechanisms underlying these distinct outcomes remain to be
deciphered, the data suggest that multiple regulatory pathways be involved in the formation of
tumor vascular network that demonstrates spatial-temporal deregulation of the interaction
between endothelial cells and mural cells. Therefore, in the evaluation of drug delivery and
therapy, several important factors mediating vascular maturation and normalization should be
taken into account, such as vessel coverage, permeability and stability, interstitial fluid pressure,
oxygen delivery, and local blood perfusion. Nevertheless, our current findings on YKL-40 in
tumor angiogenesis characterized by coupling of mural cells to endothelial cells have
demonstrated a potential therapeutic target in treatment of cancer patients that produce high
levels of YKL-40.

4.5 Methods
4.5.1 Cell Culture
GSDCs established previously were grown in DMEM supplemented with 10% FBS and
penicillin/streptomycin (39).
supplemented

with

5

HMVECs were grown in EBM-2 (Lonza, Allendale, NJ)

g/ml

hydrocortisone,

10

ng/ml

hEGF,

10%

FBS,

and

penicillin/streptomycin.

4.5.2 YKL-40 Gene knockdown
DNA oligos (19 bp) specifically targeting N-terminal (siRNA 1) or C-terminal (siRNA 2) region of
YKL-40, were selected and then templates (64 oligo nucleotides) containing these oligos were
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subcloned into a retroviral pSUPER-puro-vector (OligoEngine, Seattle, WA) (40). 293T retroviral
packaging cells were transfected with pSUPER siRNA constructs in the presence of pCL 10A1
vector using Fugene 6 (Roche, Indianapolis, IN). Forty-eight hours after transfection, the
supernatant was harvested and filtered through 0.45-m pore size filter and then the viral
medium was used to infect targeted cells. Selection with 1 g/ml of puromycin was started 48
hr after infection and the puromycin-resistant cell populations were used for subsequent
studies.

4.5.3 Immunoprecipitation and immunoblotting
Cell lysate samples were processed as described previously (Yan, Bentley and Shao, Distinct
angiogenic mediators are required for basic fibroblast growth factor- and vascular endothelial
growth factor-induced angiogenesis: the role of cytoplasmic tyrosine kinase c-Abl in tumor
angiogenesis 2008). Samples were subjected to running SDS-PAGE and PVDF membranes were
incubated with one of a series of primary antibodies against N-cadherin, VE-cadherin
(Invitrogen, Carlsbad, CA), -catenin (Santa Cruz Biotechnology, Santa Cruz, CA), YKL-40 (our
lab), VEGF (Sigma, St. Louis, MO), SMa (Abcam, Cambridge, MA), and actin (Sigma). Membranes
were then incubated with goat anti-mouse or anti-rabbit secondary antibodies (Jackson Lab, Bar
Harbor, Maine). Specific signals were detected by enhanced chemiluminescence (VWR,
Rockford, IL). For immunoprecipitation, cell lysates were incubated with either an anti-VEcadherin, N-cadherin, or-catenin antibody at 40C overnight followed by incubation with
protein G Sepharose 4 Fast Flow beads at 40C for 4 hr. The immunocomplex was extensively
washed and the samples were run for immunoblotting as described earlier.
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4.5.4 RT-PCR
Total RNA from cells was extracted with Tri-reagent (Molecular Research Inc, Cincinnati, OH).
RNA concentration and purity were determined spectrophotometrically (A260/280). cDNAs with
poly A tails were subsequently synthesized through a reverse transcriptional reaction in the
presence of 15-oligo (dT) (Promega, Madison, WI). A fragment of VEGF and GAPDH DNA was
synthesized by a polymerase chain reaction with sense primer 5’-CTTTCTGCTGTCTTGGGTGC-3’
and antisense primer 5’- GTGCTGTAGGAAGCTCATCTCTCC-3’, and sense primer 5’ATGGGGAAGGTGAAGGTCGGA-3’

and

antisense

primer

5’-CTCCTTGGAGGCCATGT-3’,

respectively.

4.5.5 MTS Assay
Cellular proliferation was measured using Cell Titer 96 Aqueous Nonradioactive Cell Proliferation
Assay Kit (Promega, Madison, WI) per the manufacturer’s instructions. Briefly, GSDCs (2x103
cells) were plated onto a 96 well plate and allowed to grow overnight. The next day, the MTS
reagent was added to the cells and incubated at 37° C for 1 hour. The plate was read at 490 nm
absorbance to determine cell proliferation.

4.5.6 Cell permeability
HMVECs or GSDCs (2 x 105cells) were loaded onto 0.4-m 24-transwells pre-coated with 100
g/ml collagen IV overnight. For cell co-culture, GSDCs (1 x 105cells) were loaded for 2 hr prior
to HMVECs (1 x 105cells). 24 hr later, Dextran conjugated with FITC (0.4 mg/ml, Invitrogen) was
added on the top of the wells for 4 hr. At various time points, an aliquot from the bottom of the
wells was measured for absorbance at 485 m.
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4.5.7 Immunocytochemistry
The method was described previously (Yan, Cao, et al. 2010). Briefly, cells were grown to subconfluence and fixed with 4% paraformaldehyde for 5 min. After permeabilization with Triton
100X, the cells were incubated with an anti-N-cadherin or VE-cadherin monoclonal antibody
(1:100, Invitrogen) at 40C overnight followed by incubation with a secondary anti-mouse or
rabbit Alexa Fluor 488 or Alxa Fluor 555 antibody (1:1000, Invitrogen) for 2 hr. Cell nuclei were
stained with DAPI. For dual staining, after incubation of the first antibody, the samples were
then incubated with a polyclonal anti--catenin (1:100, Santa Cruz) or SMa antibody (1:100,
Abcam) as described earlier. Positive staining in a single cell was defined based on each cell
recognized by nuclear staining of DAPI. The positive signal from a viewed field was quantified
with software ImageJ and then normalized with total cell numbers positive for DAPI. In some of
dual-cell culture staining analyses, in addition to nuclear DAPI counted for cell number, a specific
cell marker (e.g. VE-cad for endothelial cells) was also used to distinguish marker-positive cells
from marker-negative cells. Images were analyzed using a Nikon TE2000U inverted fluorescent
microscope.

4.5.8 Tube formation
HMVECs (2 x 104cells) were transferred onto 96-well Matrigel (BD Bioscience, San Jose, CA).
After 16 hours of incubation, tube-forming structures were analyzed. Images were analyzed
with an inverted microscope. Averages of tubules were calculated from three fields in each
sample.

For the vascular stability assay, HMVECs (2 x 104cells) and GSDCs (2 x 103cells) pre-

labeled with Calcein AM and Calcein Red (5 g/ml, Invitrogen), respectively, were mixed and
loaded onto 96-well Matrigel over 64 hours. Tubules with fluorescence were imaged and
quantified at various time points.
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4.5.9 Cell aggregation
GSDCs or HMVECs (2x106) were re-suspended in 1 mL of serum-free media containing 1mM
CaCl2 and transferred to a 2-mL Eppendorf tube. The tube was placed in a shaker at 90 rpm at
37°C for 1 hour. Finally, cells were transferred to a cell culture dish for phase contrast imaging
of cell aggregation. Aggregates were counted as colonies of 10 cells or more.

4.5.10 Scratch wound migration
GSDCs were plated at 95% confluency on a 24-well plate and allowed to grow overnight. A
sterile 200 µL tip was then used to make a scratch through the middle of the well. The wells
were washed gently twice with PBS to remove floating cells. Images were taken at time points 0
and 24 hr and the number of cells that migrated into the scratch was quantified.

4.5.11 Tumor xenografts in mice
All animal experiments were performed under the approval of Institutional Animal Care and Use
Committee of the University of Massachusetts. GSDCs expressing control vector or YKL-40
shRNA (1.5 x 105) cells in 10 µl of PBS were injected into right striatum of SCID/Beige mice. Mice
were sacrificed when mice displayed decreased locomotion.

4.5.12 Immunohistochemistry and immunofluorescence
Paraffin-embedded or frozen tumor tissue were cut to 6 m thickness and processed for
immunohistochemical analysis. In brief, samples were incubated with 3% H2O2 for 30 min to
block endogenous peroxidase activity, followed by incubation with blocking buffer containing
10% goat serum for 1 hr. The samples then were incubated at room temperature for 2 hr with a
rabbit polyclonal anti-Ki67 antibody (1:100, Invitrogen). A goat anti-rabbit secondary antibody
(1: 100, Dako Inc, Carpinteria, CA) conjugated to HRP was added for one hr. Finally, DAB
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substrate (Dako Inc) was introduced for several minutes and after washing, methyl green was
used for counterstaining. For a single and dual immunofluorescent staining, tumor specimens
were incubated with a rat anti-CD31 (1: 50, BD Pharmingen, San Diego, CA) antibody for 2 hr
followed by incubation with a goat anti-rat Alexa Fluor 555 secondary antibody (1: 250) for 1 hr.
Then the samples were similarly incubated with a mouse anti-SMa (1:500, Dako Inc) or rabbit
anti-fibrinogen antibody (1: 100, Dako Inc) followed by incubation with a goat anti-mouse or
rabbit Alexa Fluor 488 antibody (1: 250) for 1 hr. Finally, DAPI was added to stain nucleus. NIH
ImageJ software was used to quantify vessel density in the single staining of CD31, individual
density of SMa, CD31, and fibrinogen in dual staining.

4.5.13 Statistics:
Data are expressed as mean ± SE and n refers to the numbers of individual experiments
performed.

Differences among groups were determined using one-way ANOVA analysis

followed by the Newman-Keuls test. The 0.05 level of probability was used as the criterion of
significance.
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CHAPTER 5
FUTURE DIRECTIONS

5.1 Search for the YKL-40 Receptor
While we have uncovered multiple roles for YKL-40 in tumor progression, with a
particular emphasis on the molecular mechanisms of tumor vasculature (Shao, et al. 2009, R.
Francescone, et al. 2011, Faibish, et al. 2011, Francescone, Ngernyuang, et al. 2013 ), how YKL40 initiates these signaling cascades still remains unknown. The identification and
characterization of the potential receptor of YKL-40 is therefore a vital avenue to pursue for two
major reasons. First, we would gain insight into how YKL-40 works at the membrane to initiate
the activation of downstream signaling pathways. Second, and most importantly, the discovery
of the YKL-40 receptor would offer another therapeutic target for pharmaceutical development.
Inhibition of the membrane receptor could result in more potent suppression of tumor
progression, as small molecule drugs could also be developed for membrane proteins.

5.2 Validation Combination Therapy that includes Anti-YKL-40 treatment in vivo:
YKL-40 undoubtedly plays an important role in conferring radioresistance to
glioblastoma cells, especially in vitro (Pelloski, et al. 2005) (R. Francescone, et al. 2011) (Junker,
et al. 2005). However, it is not clear whether anti-YKL-40 therapy, in conjunction with radiation,
chemotherapy, and anti-angiogenic therapy would be well tolerated by the patient. Therefore, it
is of the utmost importance that more studies are done in vivo to determine the efficacy and
safety of adding an anti-YKL-40 regimen to the current “standard of care” for glioblastoma. This
would ultimately have direct clinical applications and could lead to clinical trials in humans for
the treatment of GBM.
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5.3 Summary
Vasculature is a vital source of nutrients and oxygen for an expanding tumor, and is often
considered the rate limiting step in tumor progression. Glioblastoma (GBM) is characterized by
extremely high amounts of vasculature, whether it is host or tumor derived. It remains a key
target in cancer therapy, although most treatments rely on blocking angiogenesis, leaving all
other types of vasculature unscathed. In addition, these types of therapies tend to increase the
invasion of glioblastoma cells into the normal brain, which is detrimental to patient survival.
Thus, new molecular targets unique to glioblastoma must be uncovered, and their mechanisms
fully defined, in order to develop more effective therapies. One exciting biomarker and putative
therapeutic target is the secreted glycoprotein YKL-40. It is highly expressed in the serum of
many high grade cancers and is correlated with short survival and resistance to therapies, and
this is especially true in glioblastoma. In chapter 2, I discussed work that was done in our lab
that unveiled the signaling pathways involved with YKL-40 mediated angiogenesis in
glioblastoma. In addition, we showed its ability to confer radioresistance to GBM cells. Overall,
blockade of YKL-40 prolonged the survival of mice in two distinct models, demonstrating the
therapeutic value of inhibiting YKL-40.
In chapter 3, I presented a study that illustrated the plasticity of GBM tumor cells. The stem-like
cells from a human patient with GBM could be differentiated into mural-like cells that could
form vasculature independent of endothelial cells, referred to as vasculogenic mimicry (VM). In
addition, these cells where functionally dependent on the protein Flk-1, which is the major
receptor to vascular endothelial growth factor (VEGF). On the other hand, the formation of VM
was independent of VEGF, which is important to note because most therapies target VEGF
mediated angiogenesis, highlighting the significance of inhibiting other forms of vasculature in
GBM. All in all, this study was novel and of great consequence because we established the first
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molecular mechanisms of VM formation in glioblastoma, and developed a great model system
to study the impact of mural-like tumor cells in vasculature formation in relation to other
players, including YKL-40.
As outlined in chapter 4, using the mural-like tumor cell model developed in chapter 3, and the
knowledge gained about the role of YKL-40 in angiogenesis in chapter 2, we wanted to explore
whether YKL-40 played a part in the mural-like cell function to support or create vasculature.
What was unveiled was that YKL-40 does indeed control mural-like cell function through cell to
cell contacts of tumor derived mural-like cells and host endothelial cells. This cell contacts were
critical for vessel integrity and permeability in tumor xenograft mouse models. In vitro analysis
revealed that the cadherin/catenin/actin pathway was a major component in the adhesion of
cells, and that the presence of YKL-40 was necessary to maintain cell to cell contacts through
this pathway. In sum, YKL-40 allowed rapid tumor development, by maintaining vessel stability
and a constant blood supply network within the tumor. Inhibition of YKL-40 created
hyperpermeable vessels that stunted tumor growth, prolonging mouse survival.
It is my hope that the work presented in this dissertation will provide the foundation for future
studies into the role of YKL-40 in GBM, and demonstrate the therapeutic value of targeting YKL40. Therefore, we can add another weapon to our arsenal in the fight to cure this horrible
disease and improve the quality of like for patients.
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APPENDICES

APPENDIX A
ROLE OF YKL-40 IN THE ANGIOGENESIS, RADIORESISTANCE, AND PROGRESSION OF
GLIOBLASTOMA

This is an original research article by: Francescone RA, Scully S, Faibish M, Taylor SL, Oh D, Moral
L, Yan W, Bentley B, Shao R.
Published in The Journal of Biological Chemistry.2011. April 29;286(17):15332-43.
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APPENDIX B
A YKL-40-NEUTRALIZING ANTIBODY BLOCKS TUMOR ANGIOGENESIS AND PROGRESSION: A
POTENTIAL THERAPEUTIC AGENT IN CANCERS

This is an original research article by:
Faibish M, Francescone R, Bentley B, Yan W, Shao R
Published in Molecular Cancer Therapeutics. 2011. May;10(5):742-51.
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APPENDIX C
A MATRIGEL-BASED TUBE FORMATION ASSAY TO ASSESS THE VASCULOGENIC ACTIVITY OF
TUMOR CELLS.

An original research article by:
Francescone RA 3rd, Faibish M, Shao R.
Published in The Journal of Visualized Experiments. 2011 Sep 7;(55).
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APPENDIX D
GLIOBLASTOMA-DERIVED TUMOR CELLS INDUCE VASCULOGENIC MIMICRY THROUGH FLK-1
PROTEIN ACTIVATION.

An original research article by:
Francescone R, Scully S, Bentley B, Yan W, Taylor SL, Oh D, Moral L, Shao R.
Published in The Journal of Biological Chemistry. 2012 Jul 13;287(29):24821-31.
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APPENDIX E
TRANSDIFFERENTIATION OF GLIOBLASTOMA STEM-LIKE CELLS INTO MURAL CELLS DRIVES
VASCULOGENIC MIMICRY IN GLIOBLASTOMAS

This an original research article by:
Scully S, Francescone R, Faibish M, Bentley B, Taylor SL, Oh D, Schapiro R, Moral L, Yan W, Shao
R.
Published in The Journal of Neuroscience. 2012 Sep 12;32(37):12950-60.
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APPENDIX F
TUMOR-DERIVED MURAL-LIKE CELLS COORDINATE WITH ENDOTHELIAL CELLS: ROLE OF YKL-40
IN MURAL CELL-MEDIATED ANGIOGENESIS

This is an original research article by:
Francescone R, Ngernyuang N, Yan W, Bentley B, Shao R.
Published in Oncogene. 2013 May 13. Epub.
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